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ABSTRACT 
Ventricular arrhythmias are the most important cause of sudden cardiac death (SCD) among 
adults living in industrialised nations. Genetic factors have substantial effects in determining 
population-based risk for SCD and may also account for inter-individual variability in 
susceptibility. Great progress has been made in identifying genes underlying various Mendelian 
disorders associated with inherited arrhythmia susceptibility. The most well studied familial 
arrhythmia syndrome is the congenital long QT syndrome (LQTS) caused by mutations in genes 
encoding subunits of myocardial ion channels. Not all mutation carriers have equal risk for 
experiencing the clinical manifestations of disease (i.e. syncope, sudden death). This 
observation has raised the possibility that additional genetic factors may modify the risk of 
LQTS manifestations. 
This study establishes the genetic aetiology of LQTS in South Africa and Denmark through the 
identification and characterisation of LQTS-causative mutations in five previously identified 
genes, as well as examining possible novel genetic causes of LQTS in a cohort comprising Danish 
and British probands. We have functionally characterised several of the mutations identified in 
this study and examined other cardiac phenotypes that may be explained by variants causing 
repolarisation disorders. 
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OPSOMMING 
Ventrikulêre aritmie bly die enkele belangrikste oorsaak van skielike hart dood (SCD) onder 
volwassenes wat in geïndustrialiseerde lande woon. Genetiese faktore het aansienlike gevolge 
in die bepaling van bevolking-gebaseerde risiko vir SCD en kan ook verantwoordelik wees vir 
die inter-individuele variasie in vatbaarheid. Groot vordering is gemaak in die identifisering van 
gene onderliggende verskeie Mendeliese siektes wat verband hou met geërf aritmie 
vatbaarheid. Die mees goed bestudeerde familie aritmie sindroom is die aangebore lang QT-
sindroom (LQTS) wat veroorsaak word deur mutasies in gene kode subeenhede van 
miokardiale ioonkanale. Nie alle mutasie draers het 'n gelyke risiko vir die ervaring van die 
kliniese manifestasies van die siekte (dws sinkopee, skielike dood). Hierdie waarneming het die 
moontlikheid genoem dat genetiese faktore anders as die primêre siekte-verwante mutasie kan 
die risiko van LQTS manifestasies verander. 
Hierdie studie stel die genetiese oorsake van LQTS in Suid-Afrika en Denemarke deur die 
identifisering en karakterisering van LQTS-veroorsakende mutasies in vyf voorheen 
geïdentifiseer gene, asook die behandeling van moontlike nuwe genetiese oorsake van LQTS in 
'n groep wat bestaan uit van die Deense en die Britse probands. Ons het funksioneel gekenmerk 
verskeie van die mutasies wat in hierdie studie ondersoek en ander kardiovaskulêre fenotipes 
wat deur variante veroorsaak repolarisasie versteurings verduidelik word.  
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PREFACE 
Long QT syndrome (LQTS) will be presented here as a paradigm of an inherited arrhythmia 
disorder. Such disorders are interesting as they increase the risk of developing syncope and 
sudden death. The problems associated with inherited arrhythmia disorders are that the genetic 
basis is not fully established, the knowledge of phenotype modifiers is lacking and clinical 
inference is not evidence based.  
In Chapter 1, I will provide a general over view of the clinical definitions and genetic bases of 
LQTS, short QT syndrome and Brugada syndrome (BrS) in the form of two reviews [1, 2]. 
Additionally, I have included an editorial highlighting the implications and evidence base of 
LQTS testing in clinical practice [3]. 
In Chapters 2 and 3, the genetic aetiology of LQTS in South Africa and Denmark is described in 
two papers which document the results of comprehensive genetic screening in these 
populations [4, 5]. 
In Chapter 4, CAV3 (encoding caveolin-3)was examined in a cohort of Danish and British LQTS 
probands and a genetic variant, which was identified in a family known to carry a KCNH2 
(LQT2-causing gene) LQTS-causing mutation, was evaluated with respect to its aetiological and 
clinical significance [6]. Additionally, the role of microRNAs in LQTS was examined in a subset of 
this LQTS cohort [7]. 
In Chapter 5, the role that the SCN5A gene plays in the development of mixed/overlapping 
phenotypes is discussed in two papers. The first paper presents a complex phenotype 
(LQTS/BrS) [8]; and the second paper deals with SCN5A mutations in atrial fibrillation patients 
and the prevalence of known LQT3-causing mutations in this group [9]. 
Patients with hypertrophic cardiomyopathy (HCM) are at risk of atrial and ventricular 
arrhythmias and minK (encoded by KCNE1) is reported to form part of an “electro-mechanical 
feed-back” system which links cardiomyocyte stretching to changes in ion channel function. 
Consequently, in Chapter 6, genes which encode cardiac ion channel subunits were examined as 
possible causes of HCM [10]. 
These studies have substantially enhanced our understanding of LQTS and inherited arrhythmia 
disorders, and have contributed to the much needed evidence base for LQTS and, in doing so, 
expanded our understanding of SCD. 
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CHAPTER 1: INTRODUCTION 
1.1 THE HEART 
The human heart is a muscular organ composed of four-chambers (Figure 1A) which, by 
rhythmic contractions, is responsible for pumping blood through the pulmonary and systemic 
circulation. Efficient functioning of the heart requires strict coordination of the particular 
functions of the pacemaker cells and cardiomyocytes within the myocardium (Figure 1B). These 
cells exhibit the characteristics of automaticity, excitability, conductivity and contractility. 
Automaticity, the ability to initiate an impulse (measured as an action potential (AP)), is a 
characteristic of pacemaker cells. Conductivity is the ability to propagate the AP to other areas 
of the heart. Excitability is the ability to respond to an impulse by depolarising and repolarising, 
thus propagating the AP. Finally, contractility is the ability of cardiomyocytes to mechanically 
respond to an electrical impulse by contracting. 
Cardiac muscle is structurally different to skeletal muscle in that cardiomyocytes are connected 
to one another through interlocking, porous membranes (intercalated discs) at the ends of 
adjacent cells. Gap junctions within the intercalated discs create a continuous electromechanical 
syncytium, which allows the movement of ions and consequently the propagation of an AP 
throughout the myocardium [11, 12]. 
1.1.1 CONTRACTILITY 
During a contraction (systole) both atria contract simultaneously, pumping blood to the 
ventricles – which subsequently contract, pumping the blood out of the heart. The right 
ventricle receives oxygen-poor venous blood from the right atrium and pumps it into the 
pulmonary circulation for gaseous exchange in the lungs. The left ventricle receives oxygen-rich 
arterial blood from the left atrium and pumps it into the systemic circulation (Figure 1). The 
four chambers of the heart each have a one-way valve to prevent blood from flowing backwards 
(Figure 1). To complete the contraction cycle (heartbeat), the heart muscle relaxes (diastole) 
which allows blood to fill the heart ready for the next contraction. The myocardium (layer of 
cardiac muscle within the heart wall) and the cardiac valves (tricuspid, pulmonary, mitral and 
aortic valves) (Figure 1) are key elements in ensuring the efficient pumping of blood through 
the heart. The contractility of the myocardium generates the force needed to circulate the blood 
and the valves ensure blood flows in the correct direction based on pressure differences across 
the valves. 
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Figure 1: A. A schematic diagram depicting the chambers, valves and great vessels  of the heart, blood flow is 
indicated by blue and red arrows. Blue arrows indicate the flow of de -oxygenated blood and the red arrows 
indicate the flow of oxygenated blood.  B. A diagrammatic representation of the layers of the heart wall, the 
myocardium is the thick middle layer. Figures adapted from 
http://www.nhlbi.nih.gov/health//dci/Diseases/hhw/hhw_anatomy.html and 
http://anatomyandphysiologyi.com/heart-anatomy/  
1.1.2 AUTOMATICITY, EXCITABILITY AND CONDUCTIVITY 
The efficient coordination of a synchronous heartbeat is maintained by the heart’s electrical 
system (Figure 2). All cardiomyocytes are excitable cells with respect to their ability to transmit 
an AP (Figure 2); while, automaticity is a specific characteristic of pacemaker cells. The cardiac 
conduction system (CCS) is responsible for the conduction of electrical impulses around the 
heart and is composed of several distinct anatomical structures that consist of highly specialised 
cardiomyocytes and conduction fibres (Figure 2). The sinoatrial node (SAN) is the pacemaker of 
the heart; electrical impulses are generated in the SAN more rapidly than any other part of the 
CCS. The propagation of the electrical impulse through the atrial wall initiates waves of 
depolarisation that causes the atria to contract. The atrioventricular node (AVN) conducts the 
depolarising wave through to the ventricles. The impulse is then propagated through the bundle 
of His which is a band of atypical cardiac muscle fibres specialised for conduction that originates 
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at the AVN, and then passes along the interventricular septum to the ventricles where it 
branches into the left and right bundle branches (LBB and RBB, respectively). From the LBB and 
RBB the impulse is propagated on to the Purkinje fibre network which results in depolarisation 
of the ventricular cardiomyocytes and excitation-contraction [13]. 
 
Figure 2: A schematic representation of the cardiac cycle, components of the cardiac conduction system and 
action potential wave forms from particular areas of the heart.  
AVN: atrioventricular node, CCS: cardiac conduction system, CS: coronary sinus, HB: bundle of His, 
IVC: inferior vena cava, LBB: left bundle branch, LV: left ventricle, MB: moderator band, PF: Purkinje fibres, 
PV: pulmonary vein, RA: right atrium, RBB: right bundle branch, RV: right ventricle, SAN: sinoatrial node, 
SCV: superior caval vein, VS: ventricular septum. Figure adapted from [13, 14]. 
The human cardiac excitatory process was first mapped in normal hearts by Durrer et al. 
(1970) [15]. Understanding this physiological process was the first step towards understanding 
abnormal electrical activity in arrhythmic diseases. 
1.2 ELECTROCARDIOGRAM 
The invention of Eithoven’s string galvanometer at the beginning of the 20th century provided 
the opportunity to assess the heart’s electrical activity in a non-invasive manner. The 
galvanometer greatly improved the sensitivity of recording electrical potentials and led to the 
development of the ECG technology [16]. It became possible to classify clinically occurring 
arrhythmias as to their clinical presentation, mechanism and focal origin [17]. 
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The ECG uses twelve leads, each of which connects a surface-electrode to an amplifier within the 
ECG apparatus. The electrical activity from particular parts of the heart is measured based on 
the position of the lead on the body as shown in Figure 3. As the heart beats, the electrical 
information is translated into wave patterns; Einthoven labelled the ECG waves: P, Q, R, S and T; 
these labels are still the standard nomenclature when referring to ECG waves (Figure 3). The 
cardiac electrical impulse is generated in the SAN and spreads through both atria (Figure 2). 
This electrical activity is represented by the P-wave on an ECG trace (Figure 3). When the 
impulse reaches the AVN, the bundle of His is activated and the impulse spreads via the RBB and 
LBB (Figure 2) – depolarising the ventricles. Ventricular depolarisation is represented by the 
QRS complex on an ECG trace (Figure 3). The coordinated conduction of the impulse to both 
ventricles results in ventricular contraction. The repolarisation of the ventricles (return to 
normal resting potential) is represented by the T-waves on the ECG. Thus the QT interval 
represents the duration of the ventricular action potential (Figure 3). 
 
Figure 3: A. Positions of ECG electrodes are indicated and labelled appropriately [18]. B. A schematic 
representation of the ventricular cardiomyocyte action potenti al which corresponds to the QT interval on an 
ECG trace. The phases of the action potential are indicated, these represent shifts in ion channel activity and 
consequent changes in membrane potential  [19]. C. A representative diagram of single cycle ECG pattern, the 
P wave corresponds to the firing of the SA node and depolarization of the atria; the PR interval represents 
the delay of the electrical impulse at the AV node. The QRS complex corresponds to ventricular 
depolarization while the T Wave represents ventricular repolarisation. Figure adapted from 
http://www.as.miami.edu/chemistry/2086/NEW-Chap20/NEW-Chapter%2020_part2.htm  
As the QT interval is strongly influenced by the heart rate (RR interval), it is necessary to correct 
for this influence when reporting a QT interval. Several mathematical formulas have been 
developed in order to calculate the corrected QT (QTc) interval, QTc intervals reported 
throughout this thesis have been calculated using Bazett’s formula (          ) [20]. 
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1.3 CARDIAC ARRHYTHMIAS 
Cardiac arrhythmias pose a significant health burden. The approximate ratios of people affected 
by particular heart rhythm disturbances are indicated in Table 1. Heart rhythm disturbances 
may abolish the synchronicity of the heartbeat, causing myocardial fibres to contract in a 
random, uncoordinated fashion resulting in atrial fibrillation (AF) or ventricular fibrillation (VF) 
depending on which chambers are affected. As a consequence of the frequency and societal 
impact of cardiac arrhythmias, the molecular mechanisms involved in arrhythmogenesis or the 
molecular determinants of disease have become a focus of cardiac research [21].  
Table 1: The proportion of the US population hospitalised or deceased as a result of arrhythmias in 2003, 
data taken from Rosamond et al. (2007) [22]. The ratios were calculated from the number of people 
hospitalised as a result of an arrhythmia as well as the number of people whose deaths were caused by 
arrhythmias in 2003. The number of people who developed arrhythmias or died as a result of an arrhythmia, 
which was a secondary complication to their condition,  was not included. 
Heart rhythm disturbance Approximate proportion of US population 
Arrhythmia 1:300 
AF 1:600 
VT 1:3500 
VF 1:40000 
AF: atrial fibrillation, VF: ventricular fibrillation, VT: ventricular tachycardia. 
1.3.1 TERMINOLOGY OF RHYTHM DISTURBANCES 
The normal heart rhythm is referred to as the sinus rhythm (because is it paced by the SAN), 
which results in the regular (60-100 bpm) rhythm characteristic of a normal ECG pattern 
(Figure 3). A slower than normal heart rate is called a sinus bradycardia and a faster than 
normal heart rate is called a sinus tachycardia. An aberrant heart rhythm is referred to as an 
arrhythmia; if the arrhythmia coincides with a slow or fast heart rate, it is referred to as a 
bradyarrhythmia or a tachyarrhythmia, respectively. 
Supraventricular tachycardias (SVTs) are atrial in origin and interfere with the efficient flow of 
blood into the ventricles. The most common SVTs are AF, atrioventricular nodal reentrant 
tachycardia (AVNRT) and atrioventricular reentrant tachycardia (AVRT). SVTs can be described 
as paroxysmal or incessant. A paroxysmal arrhythmia is an irregular rhythm that occurs 
infrequently, comes and goes, lasts a few minutes to hours and then stops on its own. An 
incessant arrhythmia is a continuous arrhythmia which affects atrial contractions. This in turn 
affects the ventricles. 
Ventricular tachycardias (VTs) are ventricular in origin; mild cases can effectively pump blood 
and maintain blood pressure. Serious cases, however, lead to VF, which leads to cardiac arrest, 
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hypoxia and, without medical intervention will result in death. VTs can be described as 
monomorphic or polymorphic. Monomorphic VT (MVT) manifests as a regular rhythm with 
similar QRS complexes in each ECG lead. Polymorphic VT (PVT) manifests as frequent changes 
morphology and axis of the QRS complexes on ECG. Furthermore, the duration of the VT 
episodes is another means of classification. Episodes of VT which last more than 30 seconds are 
called sustained VTs, while those which self-terminate before 30 seconds are called non-
sustained VTs. These abnormalities often occur in people with structural heart problems, such 
as an infarct from a previous heart attack or rare inherited heart defects. Although the 
functional substrate, transient initiating event and arrhythmia mechanism may differ in these 
two cases understanding the development of arrhythmias in inherited arrhythmic diseases may 
shed light on the mechanisms by which arrhythmias develop in coronary artery disease (CAD) 
and myopathy patients. 
1.3.2 MECHANISMS OF ARRHYTHMIAS 
There are three basic mechanisms of arrhythmias as illustrated in Figure 4: namely, increased 
automaticity, triggered activity and re-entry. Automaticity is a measure of the propensity of a 
fibre to initiate an impulse spontaneously. Increased automaticity causes arrhythmias by the 
inappropriate spontaneous depolarisation of cardiac tissue. Triggered activity relates to the 
occurrence of ‘afterdepolarisations’. These can occur before full repolarisation – early-
afterdepolarisations (EADs), or after full repolarisation - delayed-afterdepolarisations (DADs). 
These afterdepolarisations can become self-perpetuating if they reach threshold potential and 
trigger another afterdepolarisation, thereby generating an arrhythmia. Re-entry is the most 
common arrhythmia mechanism whereby a block of the electrical impulse causes a feedback 
“loop”. 
 
Figure 4: Mechanisms of arrhythmia generation. In all panels Trace 1 (solid line) represents the normal condition A. Trace 2 
(dotted line) represents increased automaticity, caused by inappropriate depolarisation and abnormally rapid firing. B. 
Trace 2 represents an afterdepolarisation which has not reached the threshold necessary to become self-perpetuating. 
Trace 3 represents an afterdepolarisation which has reached threshold to result in a premature ectopic AP before the next 
expected normal AP. C. Re-entry occurring between two connected zones of tissue (I and II) - as shown on the right. Trace 2 
represents a premature activation in zone II. This activation current fails to initiate firing in zone I because zone I is still 
refractory. Trace 3: This current may conduct back (red dashed line) to zone I at a time when it can respond with an AP. 
Trace 4: This AP may propagate to initiate in zone II, and the process can continue indefinitely. Image taken from [23]. 
AP: action potential, RP: refractory period, TP: threshold potential. 
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1.4 SUDDEN CARDIAC DEATH 
Sudden cardiac death (SCD), defined as death by cardiac causes occurring within one hour from 
the onset of symptoms [24], accounts for the worldwide loss of more than three million people 
per annum [25]. While the true incidence of SCD is difficult to determine [26], it has been 
estimated to range from 180,000- >450,000 [27] within the USA, this indicates that ~7-18% of 
mortality in the USA is attributed to SCD. Epidemiological studies suggest that ~90 % of SCD 
cases are a consequence of arrhythmias [28], consequently, a better understanding of 
arrhythmogenesis is required to address this issue [29]. 
Regardless of the underlying disease state, progression to SCD typically follows the same 
course: VT degenerates to VF and circulatory arrest and death [25, 30] as indicated in Figure 5. 
 
Figure 5: Pathophysiology and epidemiology of SCD [31]. 
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To date, clinical surveys have failed to define risk markers which accurately predict the risk of 
SCD for individuals in the general population. Those risk factors which have been identified 
include: abnormal cardiovascular function, e.g. left ventricular ejection fraction (LVEF) [30]; 
electrocardiographic variables, e.g. QT and QRS measurements as well as T wave alternans [29]; 
abnormalities in electrophysiological testing [31]; variation in cardiac autonomic function e.g. 
heart rate variability and baroreflex sensitivity [24] and finally, ambient ventricular 
arrhythmias [29, 30]. These predictors are appropriate for identifying risk of SCD in highly 
selected groups, such as those with CAD, congestive heart failure (CHF) and myocardial 
infarction (MI) survivors. However, as shown in Figure 6, these high risk groups make up a 
small proportion of total SCD cases per annum. Only 10% of SCD victims have a high risk profile 
[17]. Members of the general population have a low relative risk of SCD, but the absolute 
number of deaths is high [24, 29]. This indicates a need for more specific markers to identify 
risk in the general population. 
 
Figure 6: SCD incidence and total events for various population pools, showing an inverse relationship 
between risk and total number of events [25]. 
AVID: Antiarrhythmics vs. Implantable Defibrillators Trial, CAD: coronary artery disease, CHF: congestive heart failure, Hx: 
history, LVEF: left ventricular ejection fraction, MADIT: Multicentre Automatic Defibrillator Implantation Trial, 
MI: myocardial infarction, MUSTT: Multicentre Unsustained Tachycardia Trial, SCD-HeFT: Sudden cardiac death in Heart 
Failure Trial 
A popular hypothesis is that SCD is an electrical mishap, whereby functional and structural 
substrates, modulated intrinsic or extrinsic triggers such as electrolyte imbalance or drug 
intake, impact on the potential arrhythmic mechanisms universal to all hearts (Figure 7). 
Stellenbosch University  http://scholar.sun.ac.za
  Page 9 
 
Figure 7: This Venn diagram indicates the potential interactions of various cardiac factors. The factors may modulate latent 
arrhythmogenic mechanisms capable of causing sudden death [29]. 
CAD – Coronary Artery Disease, DCM – Dilated Cardiomyopathy, EMD – Electromechanical dissociation, 
HCM - Hypertrophic Cardiomyopathy, RVD – Right Ventricular Dysplasia, VT – Ventricular Tachycardia, 
VF - Ventricular Fibrillation. 
1.5 INHERITED ARRHYTHMIA DISORDERS  
Primary arrhythmogenic disorders remain the single most important cause of SCD among 
young, healthy individuals living in industrialised nations [32]. Genetic factors have substantial 
effects in determining population-based risk for SCD and may also account for inter-individual 
variability in susceptibility [33]. Inherited arrhythmia disorders encompass a group of 
syndromes with unique genetic defects and presentations but with very similar clinical 
outcomes and complications. Much progress has been made in identifying genes underlying 
various Mendelian disorders associated with inherited arrhythmia susceptibility. 
1.5.1 LONG QT SYNDROME 
Ventricular repolarisation as represented by the QT interval on an ECG recording (Figure 3 and 
Figure 8) is subject to a great deal of physiological variability with an upper limit of the QTc 
interval of 470ms in post-pubertal males and 480ms in post-pubertal females [34]. 
Pathologically prolonged QTc intervals are characteristic ECG findings in long QT syndrome 
(LQTS). QTc interval prolongation is a consequence of delayed cardiac repolarization which may 
be caused by mutations in the genes encoding cardiac ion channels or proteins which modulate 
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their function; this form of LQTS is called congenital LQTS [1]. Alternatively, and more 
frequently, delayed cardiac repolarisation and consequent QT prolongation may be acquired. 
 
Figure 8: A. Normal and prolonged ventricular action potential . B. Normal and reduced IKr currents. C. 
Normal and prolonged QT interval on an ECG. D. A schematic representation of Torsade de Pointes. Figure 
taken from [35]. 
The most frequent mechanism of acquired QT prolongation is the drug-induced inhibition of the 
IKr current (Figure 8). In both congenital and acquired LQTS, abnormal cardiac repolarisation 
predisposes to the development of torsades de pointes (TdP), a PVT frequently associated with 
LQTS and SCD (Figure 8). QTc prolongation is considered a marker of the arrhythmogenic 
potential of a drug. However, the relationship between QTc and SCD is unknown with no clearly 
defined QTc length which could be considered the “tipping point” of the risk for developing a 
potentially fatal arrhythmia [36]. A better understanding of the congenital form of LQTS will 
undoubtedly also improve our understanding of acquired LQTS. 
Congenital LQTS is the focus of the work reported here and the acronym (LQTS) has been used 
to define the congenital form of LQTS, throughout. Reviews of the genetic bases of LQTS, SQTS 
and BrS, as well as an editorial describing the implications which LQTS genetic testing have for 
personalised medicine, follow. 
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1.5.2 REVIEW 1: THE GENETIC BASIS OF LONG QT AND SHORT QT SYNDROMES: A 
MUTATION UPDATE 
 
 
 
Paula L. Hedley, Poul Jørgensen, Sarah Schlamowitz, Romilda Wangari, Johanna Moolman-
Smook, Paul A. Brink, Valerie A. Corfield and Michael Christiansen. 
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1.5.3 REVIEW 2: THE GENETIC BASIS OF BRUGADA SYNDROME: A MUTATION UPDATE 
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1.5.4 EDITORIAL: LONG QT TESTING: IMPLICATIONS FOR COMPLEX DIAGNOSIS IN 
PERSONALISED MEDICINE 
 
 
 
Michael Christiansen and Paula L. Hedley. 
 
 
Personalized Medicine 7(2):125-127, 2010. 
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HYPOTHESIS 
The primary hypothesis is that there are molecular causes of LQTS in South African and Danish 
families, and that the disease-causing mutations may be harboured in the 13 genes that have 
been previously implicated in this disorder in international studies. The causative relationships 
between mutations and disease should be carefully established. Additionally, we hypothesise 
that some of the as yet unaccounted for genetic causes of LQTS may be found in genetic 
rearrangements of these genes. Alternatively, genes involved in transcript regulation of these 
genes may be harbouring potentially pathogenic variants. Finally, we hypothesise that the 
phenotypic spectrum of LQTS-associated genes may be very broad comprising other 
arrhythmias and structural heart diseases. 
AIM 
The first facet of this project is the identification of the spectrum of LQTS-causative mutations, 
in previously identified genes, in South African and Danish population groups. The second facet 
involves the assessment of the evidence-base of “LQTS-associated genes” and the identification 
of novel genes involved in LQTS aetiology. Finally, the role LQTS-causing genes play in other 
phenotypes will be determined.
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CHAPTER 2: THE GENETIC AETIOLOGY OF LONG QT SYNDROME 
IN SOUTH AFRICA 
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PAPER 1: LONG QT SYNDROME IN SOUTH AFRICA: THE RESULTS OF 
COMPREHENSIVE GENETIC SCREENING 
 
 
 
Paula L. Hedley, Glenda A. Durrheim, Firzana Hendricks, Althea Goosen, Cathrine Jespersgaard, 
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CHAPTER 3: THE GENETIC AETIOLOGY OF LONG QT SYNDROME 
IN DENMARK 
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PAPER 2: MUTATIONS IN DANISH PATIENTS WITH LONG QT SYNDROME AND 
IDENTIFICATION OF A LARGE FOUNDER FAMILY WITH P.F29L IN KCNH2 
 
 
 
Michael Christiansen, Paula L Hedley, Juliane Theilade, Birgitte Støvring, Trond P. Leren, 
Ole Eschen, Karina M Sørensen, Anne Tybjærg-Hansen, Lilian B Ousager, Lisbeth N. Pedersen, 
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ABSTRACT: 
Background: Long QT syndrome (LQTS) is a cardiac ion channelopathy which presents clinically 
with palpitations, syncope or sudden death. More than 700 LQTS-causing mutations have been 
identified in 13 genes, all of which encode proteins involved in the execution of the cardiac 
action potential. The most frequently affected genes, covering > 90% of cases, are KCNQ1, KCNH2 
and SCN5A. 
Methods: We describe 64 different mutations in 70 unrelated Danish families using a routine 
five-gene screen, comprising KCNQ1, KCNH2 and SCN5A as well as KCNE1 and KCNE2. 
Results: Twenty-two mutations were found in KCNQ1, 28 in KCNH2, 9 in SCN5A, 3 in KCNE1 
and 2 in KCNE2. Twenty-six of these have only been described in the Danish population and 
24 of these are novel. One compound heterozygote (1.4 % of families) was found. A founder 
mutation, p.F29L in KCNH2, was identified in 5 unrelated families. Disease association, in 31.2 
% of cases, was based on the type of mutation identified (nonsense, insertion/deletion, 
frameshift or splice-site). In 22.7 % of missense mutations functional analysis was available. 
Only one novel missense mutation was not found to be possibly causative using either Polyphen-
2, SIFT or Mutation Assessor prediction servers. None of the mutations were found in 364 
Danish alleles and only three, all functionally characterised, in the Exome Variation Server, albeit 
at a frequency of < 1:1000. 
Conclusion: The genetic aetiology of LQTS in Denmark is similar to that found in other 
populations. A large founder family with p.F29L in KCNH2 was identified. In 48.4 % of 
the mutations disease causation was based on mutation type or functional analysis.
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BACKGROUND 
Long QT syndrome (LQTS) is a genetic disease of the cardiac electrical system which presents 
clinically with palpitations, syncope and sudden death [1, 2]. To date, more than 
700 disease-causing mutations have been found in 13 genes [1-3] and the total number of 
mutations is probably even larger [4]. All these genes are directly or indirectly involved in the 
execution of the cardiac action potential (AP) [2]. LQTS is a consequence of a prolongation of the 
repolarisation phase of the AP, caused by decreased activity of the repolarising inward K
+
-currents, 
Iks and Ikr, or increased late activity of the outward depolarising Na
+
-current, INa. The delayed 
repolarisation leads to the appearance of early after depolarisations (EADs), due to enhancement of 
the Na+/Ca2+-exchanger and the L- type Ca2+ channel [5]. These, together with increased 
refractoriness, may trigger malignant arrhythmias [2]. 
In Denmark, genetic diagnostics of LQTS has been performed since 1996. From 2006 the 
management of LQTS patients has followed national guidelines [6]. The genetic diagnostic work is 
centred in five University cardiology clinics and patients are offered a five-gene screen of the most 
frequently affected genes, KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2. Initially, the screen was 
performed using single strand conformation polymorphism analysis (SSCP) of the coding regions of 
the genes with intronic amplification primers [7-9]. In recent years, the mutation analysis has been 
performed by bi-directional Sanger sequencing of coding regions and all previous patients have 
been re-analysed. Here we report the disease-causing mutations identified in Danish LQTS families 
during the preceding 15 years. Furthermore, as the evidence base for considering mutations 
disease-causing is not always clear [10], and rare variants not associated with disease are found in 
controls [11], we report our reasoning for considering them disease- causing. Finally, we compare 
the distribution of mutations with that found in other population studies. 
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MATERIALS AND METHODS  
PATIENTS 
The patients were 71 Danish LQTS probands from unrelated families where mutation screening in 
the five LQTS associated genes KCNQ1, KCNH2, KCNE1, KCNE2 and SCN5A had led to identification 
of a disease-causing mutation. LQT diagnosis was based on the clinical examination of patients, 
which was performed according to guidelines issued by the Danish Cardiology Society [6] by 
specialists in cardiology from Danish cardiology departments at Rigshospitalet, Skejby Hospital, 
Aalborg Hospital, Gentofte Hospital, Haderslev Hospital and Odense Hospital. All patients had a QTC 
interval > 440 ms for men and 450 ms for women. All patients were Caucasian. A clinical 
description of patients identified through a Danish nationwide survey comprising 59 families (all 
contributing to the current survey) has recently been published [12]. 
MUTATION IDENTIFICATION 
Genomic DNA was extracted from EDTA-blood using the commercially available MaxwellTM 16 
Blood DNA purification kit on the MaxwellR 16 System (Promega Biotech AB, Nacka, Sweden). 
Genetic screening was performed by bi-directional sequencing of PCR amplified exons with 
associated flanking intronic regions. Primers were M13 extended and sequences are given in 
supplementary tables S1 and S2. A minor proportion of mutations were identified at genetic 
departments at Skejby University Hospital, Rigshospitalet as well as in Norway and the Netherlands 
using other, but similar, technologies. All probands had the coding regions of the five genes 
sequenced. . All mutations were verified by sequencing a second amplified amplicon. A large 
proportion of patients were examined for large deletions in KCNQ1, KCNH2, KCNE1, KCNE2 and a 
small part of SCN5A by multiplex-ligation-dependent amplification (MLPA) using the SALSA MLPA 
P114 kit (MRC-Holland, Amsterdam, The Netherlands). 
MUTATION AND PROTEIN NOMENCLATURE  
Mutation nomenclature uses numbering with the A of the initiation codon ATG as +1 
(www.hgvs.org/mutnomen), based on the following RefSeqs: NM_000218.2 (KCNQ1), NM_000238.2 
(KCNH2), NM_000335.4 (SCN5A), NM_000219.3 (KCNE1) and NM_172201.1 (KCNE2). All mutations 
were checked using Mutalyzer. The protein nomenclature was that used in the recent mutation 
update on LQTS [2]. 
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EVALUATION OF SEQUENCE CHANGES 
Deletions, frameshift-, splice- and nonsense mutations were considered disease-causing if not found 
in controls. Concerning missense mutations, familial segregation was ascertained if possible, but 
nuclear family size was in all cases so small that it precluded a proper linkage analysis [12]. Instead 
it was ascertained that the family did not contain affected members that did not carry the family 
mutation. Conservation of residues across several species was examined- All genetic variants were 
evaluated in 182 randomly and anonymously collected blood donor controls (364 alleles). The 
frequency of identified variants was assessed using the Exome Variant Server v.0.0.21 
(http://evs.gs.washington.edu). It was established whether genetic variants had previously been 
associated with LQTS and whether functional analysis had been performed. The potential functional 
effect of changes in amino acid composition was assessed in silico using the prediction servers 
Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/) [13], SIFT (http://sift.bii.a-star.sg) [14], and 
MutationAssessor (http://www.ngrl.org.uk/Manchester/page/mutation-assessor) [15]. 
HAPLOTYPING KCNH2 
Haplotyping was performed using the microsatellites D7S1824, D7S1826 up-stream of KCNH2 and 
D7S636, D7S3070, D7S483 and D7S1803 downstream of KCNH2 (Figure 1). CentiMorgan distances 
were obtained from the Map-O-Mat database for microsatellites 
(http://compgen.rutgers.edu/mapomat/). PCR amplicons were generated using fluorescently end-
labelled primers (available at NCBI UniSTS) at 0.4µM per primer, per reaction. A loading mix of 
0.5µl amplicon, 9µl HiDi formamide (Applied Biosciences) and 0.5µl 600LIZ size standard (Applied 
Biosystems) was prepared, and DNA products were electrophoresed on an ABI 3100 Genetic 
Analyser. Data were analysed using ABI GeneMapper software v4.0. 
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RESULT 
MUTATION SCREENING 
The results of the mutation screening are summarized in Tables 1 - 3. In the 70 families we found 
64 different mutations; 22 in KCNQ1, 28 in KCNH2, 9 in SCN5A, 3 in KCNE1 and 2 in KCNE2. All 
patients were heterozygous carriers of a single mutation, except one compound heterozygous 
proband (1.4% of families), with a p.R583G in KCNQ1 and p.A93T in KCNE1. Twenty-six of the 
mutations have only been described in Danish LQTS patients (Table 1-3), 22 have not been 
reported previously. Two mutations in KCNH2, p.F29L and p.K101E were found in 5 and 2 
unrelated families, respectively. The MLPA analysis, applied to 65 of the probands, resulted in the 
identification of a single three exon (7-9) deletion, IVS6_IVS10del, in KCNQ1. None of the mutations 
were found in 384 control alleles. 
KCNQ1 MUTATIONS 
The twenty-two mutations identified in KCNQ1 seemed evenly spread out over the gene (Table 1). 
Only three of the mutations (IVS6_IVS10del, p.H363N and p.R583G) had not previously been 
described in other populations. The IVS6_IVS10del results, theoretically, either in the excision of a 
considerable part of the protein rendering it non-functional or in haploinsufficiency due to mRNA 
surveillance mechanisms [16], and is thus considered pathogenic. The remaining missense 
mutations all affect highly conserved residues and many missense mutations have been described 
in the S2-S3 and C-terminal regions of the protein, respectively [2]. The p.R583G affects a codon, 
where another missense mutation, p.R583C, has been shown to have an electrophysiological 
phenotype similar to that expected for a LQTS-associated mutation [17]. Among the 18 mutations 
previously seen in other populations, there were two frameshift mutations, two deletions, one 
splice-site mutation and one nonsense mutation. All of these must be expected to result in 
haploinsufficiency due to mRNA surveillance mechanisms. Of the remaining missense mutations, 
four had been electrophysiologically characterized in vitro, i.e. p.V254M [18], p.L273I [18-20], 
p.Y315C [21] and p.R583C [17]. Thus, only four out of 15 LQTS- associated missense mutations (27 
%) had established electrophysiological characteristics at the molecular level. 
KCNH2 MUTATIONS 
Twenty-eight mutations were identified in KCNH2. Fourteen of these were located in the N-
terminus, and four of these were located in the Per-Arnt-Sim domain. Five were located in the C-
terminus, whereas only five were located in the pore-region (Table 2). This is surprising, as the 
majority of previously identified LQTS associated mutations in KCNH2 have been located in the pore 
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region [2]. Fifteen of the mutations have only been described in the Danish population. Nine of the 
Danish specific mutations were deletions, nonsense or frameshift mutations. The remaining eight 
Danish-specific mutations were missense mutations and all involved conserved amino acid 
residues. Among the mutations found in other populations, two were frameshift mutations and nine 
were missense mutations. Only one of these missense mutations, p. F29L, had been demonstrated 
to have an in vitro electrophysiological effect compatible with LQTS [21], so the remainder were 
considered disease-associated based on the evolutionary conservation of the involved amino acid 
residue and the absence of the mutation among 364 control alleles as well as a previously reported 
association with LQTS. The observation of the association of these mutations with LQTS in the 
Danish population corroborates their role in the causation of LQTS. Finally, a large number of 
mutations in the regions affected by the mutations described here have been associated with LQTS 
[2]. 
All the remaining missense mutations in KCNH2, except p.A913V, were conserved to the level of 
zebrafish. The p.A913V mutation changed an alanine into a valine, where the valine was found at 
the same codon in rodents. However, the mutation had previously been associated with LQTS [22] 
and in the absence of deviations from familial disease segregation, and the absence of other 
mutations in the five genes as well as of the mutation in 364 control alleles, it was considered 
disease-causing. 
SCN5A MUTATIONS 
Nine mutations were identified in SCN5A (Table 3), six of which have only been described in the 
Danish population. Four mutations have not been reported before. Two mutations were intronic 
splice-site mutations and the remaining mutations were missense mutations located in the DI, DIV 
and C-terminal regions. This distribution is compatible with the one found when accumulating all 
known SCN5A LQTS-associated mutations [2]. The splice- site mutations were considered disease-
causing because they are believed to result in aberrant mRNA splicing resulting in the synthesis of 
SCN5A ion channels with prolonged depolarisation contributing to delayed repolarisation. The 
splice mutations most likely do not result in haploinsufficiency as this would most likely give a 
Brugada syndrome phenotype [23]. One of the missense mutations, p.P2005A, has previously been 
associated with sudden infant death syndrome and shown to result in late persistent INa current, 
compatible with LQTS [24]. An in vitro electrophysiological analysis of the functional consequence 
of the p.L1785Q mutation has shown that it results in increased late persistent INa current, but also 
in a reduction of the total INa (Kanters et al., submitted), suggesting that the electrophysiological 
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phenotype may be a combination of Brugada syndrome and LQTS, as previously described for 
SCN5A mutations [25], e.g. the E1784K mutation [26]. The remaining missense mutations interfere 
with conserved residues and have not been found in controls; further the mutations p.F1596I and 
p.V1597M, are located in the C-terminal part of SCN5A, where mutations causing LQTS are 
particularly frequent [2]. The rare polymorphism p.D1819N, known to be associated with increased 
QT-interval in normal individuals [27], was found in a single p.F29L family and not considered 
pathogenic, despite being previously reported as associated with LQTS [28] The C-terminally 
located mutations are likely to interfere with fast inactivation of the INa current [29]. Likewise, the 
remaining missense mutations, p.G319S, p.R340W and p.V411M, are located in the DI-S5- S6 region, 
a region with a high frequency of LQTS-associated mutations [2]. 
KCNE1 MUTATIONS 
Three mutations were found in KCNE1, two of which, p.G60D and p.A93T, have only been found in 
the Danish population and have not been reported before. The p.A93T was found associated with 
p.R583G in KCNQ1 in an isolated proband, where family data were not attainable. The p.G60D and 
p.D76N interfered with amino acid residues conserved in human, rat, mouse, cow and frog, whereas 
the alanine at residue 93 was only conserved in mouse, rat, cow and human. However, the N-
terminus of frog minK is not conserved at all from amino acid residue 85 – 105 in the human 
sequence (corresponding to residue 80 – 95 in the frog minK sequence). However, the missense 
mutations p. Y81C, p.W87R, p.R98W, and p.P127T – as well as p.D76N, located in the cytoplasmic C-
terminus of minK, have previously been associated with LQTS [2]. 
KCNE2 MUTATIONS 
Two mutations were found, p.I57T and p.V65M, both previously described in other populations as 
associated with LQTS [28, 30] and shown [31] to interfere with Kv7.1 function in a way compatible 
with an association with LQTS. Both interfered with highly conserved residues and were not found 
in 384 control alleles. 
DISEASE CAUSATION 
The association between a mutation and disease is of paramount importance when the mutation 
findings are used for cascade screening and clinical management as is the case in Denmark [12]. 
This is a particular problem when family data are not sufficient to establish linkage. As none of the 
mutations are present in the 364 control alleles and not in the Exome Variant Server, except for 
p.P2005A in SCN5A, p.D76N in KCNE1 and p.I57T in KCNE2, that were present, but with frequencies 
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< 1:1000, it is unlikely that they are polymorphisms. Looking at the mutations given in table 1 – 3 it 
is seen that 31.2 % are frame-shift, splice-site- nonsense- or indel mutations. Such mutations have a 
direct effect on the integrity of the polypeptide chain and are considered explanatory for LQTS. 
However, the remaining 68.8 % are missense mutations that need to be differentiated from the 
naturally occurring functionally insignificant non-synonymous variants in the same proteins. A 
classical method of supporting disease causality in LQTS is electrophysiological examination of 
mutated channel proteins to disclose a reduction in repolarising K
+
- current (KCNQ1, KCNH2, 
KCNE1, KCNE2) or late persistence of depolarising Na
+ 
- current (SCN5A) [2]. Such information was, 
however, only available for 22.7 % of the missense mutations, table 1-3. 
We used the prediction servers Polyphen-2, SIFT and Mutation Assessor to assess the significance 
of all the missense mutations for interference with protein function. The results are given in table 4. 
It is seen that the majority of mutations where an electrophysiological assessment was available 
(p.V254M, p.L273F, p.Y315C in KCNQ1, p.F29L in KCNH2, p.L1785Q in SCN5A, p.D76N in KCNE1, 
p.I57T and p.V65M in KCNE2) were expected to have an effect on protein function. Two mutations, 
p.R583C in KCNQ1 and p.P2005A in SCN5A were not found to be disruptive of protein function, 
despite functional significance in vitro. Thus, there seems to be a reasonable sensitivity for the 
prediction servers. The remaining, not functionally characterised, missense mutations, except 
p.P73T in KCNQ1, and the remaining mutations in codon 583 of KCNQ1 as well as p.A913V in 
KCNH2, were all found to be at least possibly disruptive of protein function. 
THE FOUNDER MUTATIONS IN KCNH2 
Two of the missense mutations, p.F29L [21] and p.K101E [32], were found in five and two 
“unrelated” families, respectively. Haplotype analysis, using six polymorphic microsatellite markers, 
spanning 24.6cM, flanking the KCNH2 gene at distances ranging from 10.1Mb 3’ to 2.9Mb 5’ as 
shown in Figure 1, demonstrated that both mutations were founder mutations (Table 5). 
POPULATION DISTRIBUTION OF MUTATIONS 
The distribution of Danish LQTS mutations is compared with four other large mutation surveys 
comprising verified LQTS patients in Table 6. The proportion of KCNQ1 mutations seems to be 
lower in Danish patients, 34.3 %, than in other populations, where the proportion of KCNQ1 
mutations ranged from 39.4 % - 48.6 %. This trend was not significant, however, using a Chi-Square 
test. The proportion of KCNH2 mutations in Denmark is within the range seen in the other 
populations, whereas the proportion of patients with mutations in the three rarely affected genes, 
SCN5A, KCNE1 and KCNE2 is considerably higher, 21.9 %, than seen in the other populations (range: 
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10.7 % - 16.2 %). The distribution of mutation types does not seem to differ substantially between 
the populations. Likewise, the frequency of compound heterozygosity was very similar in the 
populations where it was established. In a Norwegian study no compound heterozygotes were 
convincingly demonstrated, but 18 cases of Jervell and Lange-Nielsen syndrome had been found 
[33]. 
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DISCUSSION 
We have identified 64 different mutations in 70 Danish LQTS families referred for five- gene 
screening. This is by far the highest number of different mutations identified per capita in any 
country and it amounts to approximately 1: 72.000 inhabitants. The signature of the genetics of 
LQTS in Denmark is that of many “private” mutations (Table 1-3). With respect to this considerable 
inter-allelic and inter-genic variation, the Danish mutation spectrum is similar to that found in other 
populations (Table 6). However, there was a trend, albeit not significant, that the proportion of 
mutations in KCNQ1 is reduced and the proportion of mutations in SCN5A, KCNE1 and KCNE2 
correspondingly increased in the Danish LQTS patients. The same tendency is registered when 
comparing the Danish mutation spectrum to a collection of mutations identified in the five genes in 
persons referred for LQT testing, but where no knowledge on the clinical phenotype was available 
[4]. The relatively high frequency of mutations in the more rarely affected genes stresses the need 
of performing a five-gene screen when establishing the aetiology of individual Danish LQTS 
families. 
The patients described here were studied and collected over a long span of years, from 1996– 2010. 
In this period the clinical picture of LQTS was better defined, the possibility of referral for genetic 
analysis increased and the indication for genetic analysis in LQTS cases was established in 2006 [6]. 
Consequently, it is very difficult to establish a success rate for the genetic screening across this 
period. But it is probably comparable to the 70% reported from Norway in a much smaller 
collection of mutations [33]. Likewise, we cannot really state anything about the cost-effectiveness 
of including more genes in the basic screen or the suitability or cost-effectiveness of MLPA analysis 
of the five genes. A large proportion of cases, 65/70 had MLPA analysis performed in order to 
detect larger insertion/deletion mutations and a single case with a three exon deletion in KCNQ1 
was identified. However, considering the relatively low cost of MLPA analysis and the possibility to 
detect deletions that would have escaped classical Sanger sequencing, our data suggests that MLPA 
analysis – or more extensive methods for detection of minor structural abnormalities - should be 
part of the five gene screen as the frequency of deletions (1.4%) is comparable to that of KCNE 
mutations. 
In general, disease causation was based on the identification of a mutation that; either resulted in a 
deletion or a frameshift, introduced a stop codon or disrupted correct splicing. In the case of 
missense mutations, the mutation should involve the exchange of a conserved amino acid and not 
be present in > 100 control alleles. If the mutation had previously been associated with LQTS this 
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strengthened the argument for disease-causation. Functional assessment was not available for 
novel mutations. However, a large proportion, 48.4 %, of mutations was well classified following 
the application of the mutation type principle and functional in vitro assessment. None of the 
mutations were present in Danish controls and three were found with very low frequencies in the 
EVS server. The remaining missense mutations all, with two exceptions, were positive for 
disrupting protein function in one or several prediction servers. As the servers had a reasonable 
sensitivity, 8/10 functionally characterised mutations were correctly classified, they seem useful, 
but detailed analyses on larger datasets are necessary to establish specificity. Despite the promising 
performance of protein function interference prediction servers it will still be of great significance 
to be able to perform a functional analysis of identified novel variants. 
Interestingly, this study and a subsequent survey of the cardiology clinics revealed that Andersen 
syndrome, despite being originally described in Denmark [34], as well as Jervell and Lange-Nielsen 
syndrome and Timothy syndrome patients, are not found in Danish cardiology clinics (Kanters, 
pers.com.). 
The identification of a large KCNH2 p.F29L founder family, comprising 7.1 % of Danish LQTS 
families, is interesting, and the location of the family in the Northern part of Jutland, where it 
constitutes ca. 50% of affected families makes it easier to genotype patients from this part of 
Denmark. The p.F29L mutation has previously been found in North America [21] in a family of 
Northern European origin (Splawski, pers. com.). The mutation has been found to have an 
electrophysiological effect in vitro compatible with LQTS [21]. 
Each LQTS family has to be carefully examined as there is a risk of compound heterozygosity or 
digenic inheritance. Our data suggest that this risk is similar to that reported in other countries 
(Table 6). The clarification of the individual significance of either mutation in a family with a 
compound heterozygous index patient requires cascade screening to be performed and 
identification of carriers of the single mutations. In our experience this is rarely possible due to the 
small size of families [12]. 
The translation of molecular findings in LQTS patients into patient-specific clinical management 
decisions is difficult due to the low level of strict evidence, the complexity of the genetics, including 
the existence of genetic modifiers of phenotype [10]. Some of these problems may be alleviated if 
the use of patient-specific pluripotent stem cells turns out to give relevant information [35]. 
However, until such new approaches become routine, it is, with reference to the large role played 
by the use of previously reported information on disease-causation, important that all mutation 
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findings and clinical as well as molecular follow-up of mutations are made available to the larger 
scientific community. 
CONCLUSIONS 
The Danish spectrum of LQTS causing mutations is very similar to that of the rest of the world, even 
though the frequency of KCNQ1 mutations seems relatively reduced and the proportion of 
mutations in rarely affected genes increased. A considerable proportion of novel mutations were 
identified, but they were distributed on the genes largely as seen elsewhere. Despite a shortage of 
functional information and a long collection period nearly all mutations identified were reasonably 
classified as causative. The identification of a large founder family with p.F29L in KCNH2 may 
become of importance for local patient management as well as studies into the prevention of 
sudden cardiac death in LQT2. Sharing of genotype and phenotype data as well as development of 
improved in silico predictions of functional consequences of mutations will improve the 
management of LQTS.
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LEGENDS TO FIGURES 
FIGURE 1. Location of microsatellite markers used in haplotyping the p.F29L and 
p.k101E mutations in KCNH2.
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Table 1. Mutations identified in KCNQ1. 
Gene 
KCNQ1 
cDNA 
NM_000218 
Protein 
NP_000209 
Mutation 
Type 
Genomic 
Region 
Protein 
Region 
Phenotype References 
 c.217C>A p.P73T Missense Exon_01 N-term RWS [4, 22] 
DK c.470T>G p.F157C Missense Exon_02 S2 RWS [36] 
 c.572-576del p.L191fs Frameshift Exon_03 S2-S3 RWS [4, 37] 
 c.592A>G p.I198V Missense Exon_03 S2-S3 RWS [4] 
 c.674C>T p.S225L Missense Exon_04 S3-S4 RWS [4, 38] 
 c.667C>T p.A226V Missense Exon_04 S3-S4 RWS [4, 39] 
 c.760G>A* p.V254M Missense Exon_05 S4-S5 RWS [4, 18, 39-44] 
 c.817C>T* p.L273F Missense Exon_06 S5 RWS [4, 18-20, 39, 43, 44] 
 c.905C>T p.A302V Missense Exon_06 Pore RWS [4, 40] 
 c.944A>G* p.Y315C Missense Exon_07 Pore RWS [4, 38-40, 45-47] 
 c.1015-1017del p.F339del Deletion Exon_07 S6 RWS [48] 
DK IVS6_IVS10del Unknown Deletion Exon_07-Exon_9 Unknown RWS This study 
 c.1017-1019del p.F340del Deletion Exon_07 S6 RWS [4, 39, 43, 49] 
 c.1032G>A p.A344sp Splice-site IVS_07 C-term RWS [4, 40, 43, 44, 50-53] 
 c.1048G>A p.G350R Missense Exon_08 C-term RWS [4, 54] 
DK c.1087C>A p.H363N Missense Exon_08 C-term RWS [2, 44] 
 c.1096C>T p.R366W Missense Exon_08 C-term RWS [4, 9, 40, 44, 47] 
 c.1202insC p.P400fs Frameshift Exon_09 C-term RWS [4, 39, 55] 
 c.1588C>T* p.Q530X Nonsense Exon_12 C-term RWS [4, 20, 39, 43, 56, 57] 
 c.1747C>T* p.R583C Missense Exon_15 C-term RWS [17, 43] 
DK c.1747C>G p.R583G Missense Exon_15 C-term RWS This study 
 c.1748G>A p.R583H Missense Exon_15 C-term RWS [54] 
DK: Only seen in patients of Danish origin. *In vitro functional characterisation performed. RWS: Romano-Ward syndrome
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Table 2. Mutations identified in KCNH2. 
Gene 
KCNH2 
cDNA 
NM_000238 
Protein 
NP_000229 
Mutation 
Type 
Genomic 
region 
Protein 
Region 
Phenotype References 
DK c.65T>C p.F22S Missense Exon_01 N-term RWS This study 
 c.87C>A* p.F29L Missense Exon_01 N-term RWS [4, 21, 44] 
DK c.88-90del p.I30del Deletion Exon_01 N-term RWS This study 
 c.221C>T p.T74M Missense Exon_02 PAS RWS [4, 54] 
DK c.234_241dupTGCCGCGC p.A83fs Frameshift Exon_02 PAS RWS This study 
DK c.287T>C p.I96T Missense Exon_02 PAS RWS [8] 
DK c.301A>G p.K101E Missense Exon_02 PAS RWS [8, 32] 
DK c.326T>C p.L109P Missense Exon_03 PAS RWS This study 
DK c.446insC p.R148fs Frameshift Exon_03 N-term RWS This study 
 c.453delC p.P151fs Frameshift Exon_03 N-term RWS [58] 
 c.526C>T p.R176W Missense Exon_04 N-term RWS [58] 
DK c.552-560del p.G184-G188del Deletion Exon_04 N-term RWS This study 
 c.1096C>T p.R366X Nonsense Exon_05 N-term RWS [4, 8] 
DK c.1199T>A p.I400N Missense Exon_06 N-term RWS [8] 
 c.1283C>T p.S428L Missense Exon_06 S1-S2 RWS [54] 
DK c.1286delC p.S428fs Frameshift Exon_06 S1-S2 RWS [59] 
DK c.1591-1671del p.R531-L539del Deletion Exon_07 S4-S5 RWS This study 
 c.1682C>T p.A561V Missense Exon_07 S5 RWS [4, 38, 43, 60] 
DK c.1714G>C p.G572R Missense Exon_07 S5-pore RWS [61] 
 c.1750G>A p.G584S Missense Exon_07 Pore RWS [43, 58] 
 c.1862G>A p.S621N Missense Exon_07 Pore RWS [8, 62, 63] 
 c.1886A>G p.N629S Missense Exon_07 Pore RWS [4, 64] 
 c.1898A>G p.N633S Missense Exon_07 Pore-S6 RWS [64] 
DK c.2111_2114dup p.W705fs Frameshift Exon_08 C-term RWS This study 
DK c.2573T>C p.I858T Missense Exon_10 C-term RWS This study 
 c.2738C>T p.A913V Missense Exon_12 C-term RWS [4, 22] 
 c.2768delC p.P923fs Frameshift Exon_12 C-term RWS [65] 
DK c.3090-3102del p.S1029fs Frameshift Exon_13 C-term RWS This study 
DK: Only seen in patients of Danish origin. *In vitro functional characterization performed. RWS: Romano-Ward syndrome.
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Table 3. Mutations identified in SCN5A, KCNE1 or KCNE2. 
Gene cDNA Protein Mutation 
Type 
Genomic 
Region 
Protein 
Region 
Phenotype References 
SCN5A NM_000335 NP_000326 
DK c.611+G>A Intronic splice Splice-site IVS5 D1-S3 RWS This study 
DK c.955C>A p.G319S Missense Exon_08 D1-S5-S6 RWS [7] 
 c.1018C>T p.R340W Missense Exon_09 D1-S5-S6 RWS [4] 
DK c.1141-3C>A Intronic splice Splice-site IVS9 D1-S6 RWS This study 
 c.1231G>A p.V411M Missense Exon_10 D1-S6 RWS [4, 22] 
 c.4783T>A p.F1595I Missense Exon_27 DIV-S3 RWS [4] 
DK c.4786G>A p.V1596M Missense Exon_27 DIV-S3 RWS This study 
DK c.5354T>A* p.L1785Q Missense Exon_28 C-term RWS This study 
 c.6013C>G* p.P2005A Missense Exon_28 C-term RWS [24] 
KCNE1 NM_000219 NP_000210      
DK c.179G>A p.G60D Missense Exon_03 TM RWS This study 
 c.226G>A* p.D76N Missense Exon_03 Cyto RWS [4, 43, 65-68] 
DK c.277G>A p.A93T Missense Exon_03 Cyto RWS This study 
KCNE2 NM_172201 NP_751951      
 c.170T>C* p.I57T Missense Exon_02 TM RWS [4, 28, 30, 31, 69, 70] 
 c.193G>A* p.V65M Missense Exon_02 TM RWS [31] 
DK: Only seen in patients of Danish origin. *In vitro functional characterization performed. RWS: Romano-Ward syndrome.
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Table 4. In silico functional analysis of missense variants. 
Gene Protein Polyphen-2 SIFT MutationAssessor 
KCNQ1 p.P73T 0 0 0 
KCNQ1 p.F157C 0 1 2 
KCNQ1 p.I198V 1 1 1 
KCNQ1 p.S225L 1 1 1 
KCNQ1 p.A226V 2 1 2 
KCNQ1 p.V254M 2 1 2 
KCNQ1 p.L273F 2 1 2 
KXNQ1 p.A302V 2 1 2 
KCNQ1 p.Y315C 2 1 3 
KCNQ1 p.G350R 2 1 2 
KXNQ1 p.H363N 1 1 2 
KCNQ1 p.R366W 2 1 2 
KCNQ1 p.R583C 1 0 1 
KXNQ1 p.R583G 0 0 1 
KCNQ1 p.R583H 0 0 1 
KCNH2 p.F22S 2 0 2 
KCNH2 p.F29L 0 1 2 
KCNH2 p.T74M 2 1 2 
KCNH2 p.I96T 1 1 2 
KCNH2 p.K101E 0 1 3 
KCNH2 p.L109P 1 0 2 
KCNH2 p.R176W 2 1 0 
KCNH2 p.I400N 2 1 2 
KCNH2 p.S428L 0 0 2 
KCNH2 p.A561V 2 1 2 
KCNH2 p.G572R 2 1 2 
KCNH2 p.G584S 1 0 0 
KCNH2 p.S621N 1 1 3 
KCNH2 p.N629S 2 1 2 
KCNH2 p.N633S 1 0 1 
KCNH2 p.I858T 1 1 2 
KCNH2 p.A913V 0 0 0 
SCN5A p.G319S 0 0 2 
SCN5A p.R340W 1 1 0 
SCN5A p.V411M 2 1 3 
SCN5A p.F1595I 0 0 2 
SCN5A p.V1596M 1 1 2 
SCN5A p.L1785Q 2 1 3 
SCN5A p.P2005A 0 0 0 
KCNE1 p.G60D 2 1 2 
KCNE1 p.D76N 1 0 2 
KCNE1 p.A93T 0 0 1 
KCNE2 p.I57T 2 1 1 
KCNE2 p.V65M 2 1 1 
Polyphen-2 scores: 0: benign, 1 possibly damaging for function; 2: Probably 
damaging for function. SIFT scores: =: Tolerated and 1: Not tolerated, Mutation 
Assessor scores; 0-1: no functional effect, 2-3: functional effect on protein function  
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Table 5. Haplotyping of the p.K101E and p.F29L families. The ancestral alleles are indicated blue 
or red text with regard to each mutation. Alleles are represented by approximate number of 
repeats. 
 ped 
33 
ped 
135 
ped 
39 
Ped 
89 
Ped 
523 
ped 
779 
ped 
248_641_795 
D7S1824 0307 0104 08 06 02 02 02 
D7S1826 07 07 07 07 07 07 07 
KCNH2 101E 101E 29L 29L 29L 29L 29L 
D7S636 07 07 04 04 04 04 04 
D7S3070 08 08 06 06 08 06 06 
D7S483 06 06 08 08 07 08 08 
D7S1807 0108 06 02 02 04 02 02 
Table 6. Distribution of mutations and mutation types in this study and four other 
large studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Percentage of families.
 This 
study 
Berge et al 
(2008) [33] 
Napolitano et al 
(2005) [54] 
Tester et al 
(2005) [22] 
Splawski et al 
(2000) [43] 
Number of  
mutations 
64 37 233 211 177 
KCNQ1 (%) 34.3 42.6 48.6 41.7 39.4 
KCNH2 (%) 43.8 46.3 38.8 42.2 51.5 
SCN5A (%) 14.1 9.3 10.1 15.2 6.1 
KCNE1 (%) 4.7 1.9 1.7 0.5 2.3 
KCNE2 (%) 3.1 0.0 0.7 0.5 2.3 
Mutation type      
Missense (%) 68.8 64.9 72.0 75.0 72.3 
Nonsense (%) 3.1 13.5 5.1 5.7 6.2 
Deletion (%) 9.4 2.7 14.1 2.5 5.0 
Frameshift (%) 14.1 13.5 6.1 11.4 9.6 
Splice site (%) 4.7 5.4 2.7 4.3 6.7 
Compound 
heterozygotes (%)* 
1.4 0 3.9 5.4 n.a. 
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FIGURE 1
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CHAPTER 4: AN EXAMINATION OF PUTATIVE NOVEL GENETIC 
CAUSES OF ARRHYTHMIC SYNDROMES 
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PAPER 3: THE ROLE OF CAV3 IN LONG QT SYNDROME: CLINICAL AND 
FUNCTIONAL ASSESSMENT OF A CAVEOLIN-3/KV11.1 DOUBLE 
HETEROZYGOTE VERSUS CAVEOLIN-3 SINGLE HETEROZYGOTE 
 
Paula L. Hedley, Jørgen K. Kanters, Maja Dembic, Thomas Jespersen, Lasse Skibsbye, 
Frederik H Aidt, Ole Eschen, Claus Graff, Elijah R. Behr, Sarah Schlamowitz, Valerie Corfield, 
William J McKenna and Michael Christiansen. 
 
 
Circulation: Cardiovascular Genetics 2013; 6:452-461. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(2012 Impact Factor of CIRCCVG is 6.2) 
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PAPER 4: MICRORNAS IN CARDIAC ARRHYTHMIA: THE SEQUENCE 
VARIATION OF MIR-1 AND MIR-133A IN LONG QT SYNDROME 
 
 
Paula L. Hedley, Anting L. Carlsen, Kasper M. Christiansen, Jorgen K. Kanters, Elijah R. Behr and 
Michael Christiansen. 
 
 
SUBMITTED to SCLI 2013. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(2012 Impact Factor of SCLI is 1.29)  
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Figure 1 
 
 
 
 
 
Figure 2
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Figure 3 
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CHAPTER 5: SODIUM CHANNEL DISEASE 
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PAPER 5: FLECAINIDE PROVOCATION REVEALS CONCEALED BRUGADA 
SYNDROME IN A LONG QT SYNDROME FAMILY WITH A NOVEL L1786Q 
MUTATION IN SCN5A 
 
Jorgen K Kanters, Lei Yuan, Paula L. Hedley, Birgitte Støvring, Poul E Bloch-Thomsen, Morten 
Grunnet, Michael Christiansen, Thomas Jespersen. 
 
 
Circulation Journal SUBMITTED, 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(2012 Impact Factor of Circ J is 3.58) 
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ABSTRACT 
Background: Mutations in SCN5A, encoding the cardiac sodium channel Nav1.5, can result in 
both long QT type 3 (LQT3) and Brugada syndrome (BrS). However, a few mutations have 
shown an overlapping phenotype in single patients as well as between family members. Long 
QT syndrome is characterized by a prolonged QT interval and a prerequisite for a BrS diagnosis 
is an ST elevation in the right precordial leads of the electrocardiogram (ECG). These ST 
elevations are dynamic and may only appear after sodium channel blockage. Hence, diagnosing 
BrS patients can be difficult. 
Results: In a Danish family suffering from long QT syndrome, a novel missense mutation in 
SCN5A, changing a leucine residue into a glutamine residue at position 1786 (L1786Q) was 
found to be present in heterozygous form co-segregating with prolonged QT-interval. The 
proband presented with an aborted cardiac arrest, and his mother died suddenly and 
unexpectedly at the age of 65. Flecainide treatment revealed coved ST elevation in all mutation 
carriers. Electrophysiological investigations of the mutant in HEK293 cells revealed a reduced 
peak current, a negative shift in inactivation properties and a positive shift in activation 
properties, compatible with BrS. Furthermore, the sustained (INa,late) TTX sensitive sodium 
current was found drastically increased, explaining the association between the mutation and 
LQT syndrome. 
Conclusion: The L1786Q mutation is associated with a combined LQT3 and concealed BrS 
phenotype explained by gating characteristics of the mutated ion channel protein. Hence, 
sodium channel blockade should be considered in clinical evaluation of apparent LQT3 patients.  
Keywords: LQTS, BrS, SCN5A, electrophysiology, comorbidity
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INTRODUCTION 
Mutations in the SCN5A gene, encoding the voltage gated cardiac sodium channel, can lead to a 
multitude of diseases1 including long QT syndrome (LQTS), Brugada syndrome (BrS)2, 
progressive cardiac conduction defect disease (CCD)3, sinus node disease4, and dilated 
cardiomyopathy5. Many of the mutations in SCN5A are only linked to one of these diseases, 
although combined phenotypes like BrS + LQTS6 or BrS + CCD3 have been described. In the 
latter family it was noted that CCD and BrS ran in separate branches of the family despite having 
the same SCN5A mutation (G1406R)3, suggesting that other genetic factors may play a role. 
These additional genetic factors may be polymorphisms in other genes which have been shown 
to influence the QT interval in control populations7, as well as congenital 8-10 and acquired LQTS 
cohorts10. There is a large overlap in ECG phenotypes between healthy and affected subjects 
complicating the clinical diagnosis of both LQTS and BrS. Approximately 10 % of LQTS mutation 
carriers have a normal QT interval11. Although the prognosis of LQTS mutation carriers with 
normal QT intervals is generally better than in carriers with a prolonged QT interval there is 
still an increased risk of sudden cardiac death, warranting treatment with beta blockers and/or 
implantable cardioverter defibrillator (ICD)12. The ECG phenotype in BrS is even more 
complicated by intraindividual variability, with the occasional normalization of ST segment 
elevation occurring in many carriers. Furthermore, it is well known from BrS13 that it is not 
uncommon for healthy subjects in screening studies to show either an ST segment elevation in 
the right precordial leads or a shortened QT interval. Unless coexisting with symptoms or a 
family history these ECG parameters may be normal variants without association with sudden 
cardiac death. LQTS in patients with a SCN5A mutation is due to gain-of-function of the late 
sodium current, categorized as LQT3, leading to an increased persisting depolarizing late 
sodium current prolonging the cardiac action potential. In contrast, BrS caused by SCN5A 
mutations is due to a loss-of-function of the sodium channel. This can be caused either by 
reduced INa peak amplitudes, negative voltage shift in steady-state inactivation, positive shift in 
activation, reduced release from inactivation or any combinations of these changes in gating. As 
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the reduction in the transient sodium current in SCN5A BrS patients occurs in the initial part of 
the action potential (phase 1), whereas the persistent late sodium current in SCN5A LQTS 
patients are active throughout the whole action potential, coexistence of the two apparent 
opposing sodium channel phenotypes is possible.  
Here we describe a family with a novel SCN5A mutation (L1786Q) which presented with a 
clinical LQTS phenotype. Due to subtle early repolarization, an atypical arrhythmia initiation 
mechanism and the location of the SCN5A mutation near the position of other mutations 
underlying mixed phenotypes, we performed a Flecainide test in both the proband and the 
other SCN5A L1786Q gene carriers revealing a clear type 1 ST segment elevation pattern 
indicating BrS. 
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METHODS 
FLECAINIDE TEST 
Flecainide 2 mg/kg bodyweight (maximal 150 mg) was injected over 10 min into a cubital vein 
with simultaneous ECG recordings during flecainide administration and 30 min afterwards. 
CONSERVATION SCORE 
The conservation score was calculated as described by Jons et al.14 with the ten sodium channels 
(SCN1A-SCN11A) in figure 1 as reference values. A score of 1 indicates maximal conservation 
and 0 no conservation. 
GENETIC TESTING 
Mutation screening of SCN5A was performed with capillary array electrophoresis (CAE) single 
stranded conformation polymorphism analysis (SSCP)15, 16 on genomic DNA isolated from blood, 
followed by direct DNA sequencing of aberrant conformers. The primers used are described 
previously in detail16. The proband was also screened for mutations in KCNQ1, KCNH2 (HERG), 
KCNE1 (MinK), and KCNE2 (MiRP1). Primer sequences and conditions are available upon 
request (mic@ssi.dk). The mutation was denoted based on the full-length 2,016 amino acid 
splice variant (Genebank NM_198056.2 / NP_932173.1). 
DNA CONSTRUCTS 
Human SCN5A (hH1) in pcDNA3 was a gift from Dr. H. Abriel (Lausanne University). The 
L1786Q mutation was introduced into pcDNA3-hSCN5A by the use of overlapping 
oligonucleotides followed by full plasmid PCR. The integrity of the sub-cloned construct was 
verified by sequencing. 
PATCH-CLAMPING 
For electrophysiological studies, HEK293 cells were transiently co-transfected with 0.3 μg Wild-
Type (WT) or L1786Q Nav1.5 encoding constructs together with 0.2 μg of pcDNA3-EGFP as a 
reporter gene, using Lipofectamine (Invitrogen, USA) according to the manufacturer 
instructions. Measurements were performed 1–3 days after transfection. Whole-cell currents 
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were measured at 37±1 °C, except for the measurements of the sustained current, which were 
done at room temperature. The internal pipette solution (mM) was: CsCl 60, Cesium aspartate 
70, CaCl2 1, MgCl2 1, Hepes 10, EGTA 11, Na2ATP 5, pH 7.2, with CsOH; external solution (mM): 
NaCl 130, CsCl 5, CaCl2 2, MgCl2 1.2, Hepes 10, glucose 5, pH 7.4, with CsOH. Measurements were 
controlled with Pulse software (HEKA Elektronik, Lambrecht, Germany) and using an EPC-9 
amplifier (HEKA Elektronik, Lambrecht, Germany). Borosilicate glass pipettes were pulled on a 
DPZ-Universal puller (Zeit Instrumente, Munich, Germany). The pipettes had a resistance of 1.5–
2.5 MΩ when filled with intracellular solution. The series resistances recorded in the whole-cell 
configuration were 2–4 MΩ and were compensated (80 %). No leak subtraction was performed. 
The seal resistance was in all experiments above 1.5 GΩ, and for the sustained current 
measurements above 2 GΩ. INa was blocked with 50 μM tetrodotoxin (TTX) (Alomone labs, 
Jerusalem, Israel). The sustained current data shown in Figure 2 and 3 is an average value of the 
last 50 ms (450-500 ms) of the voltage steps. Series resistance was < 10 MΩ during the entire 
experiment. Update was performed between each sweep. 
Data analysis: Peak current densities were measured during an activation protocol and INa 
densities (pA/pF) were obtained by dividing the peak INa by the cell capacitance. For the 
activation and steady-state inactivation curves, data from individual cells were fitted with a 
Boltzmann equation, y(Vm) =1/[1 + exp[(Vm-V1/2)/K]], in which y is the normalized current or 
conductance, Vm the membrane potential, V1/2 the voltage at which half of the channels are 
activated or inactivated, and K the slope factor. Electrophysiological data were analyzed using 
Excel (Microsoft), Igor Pro (Wavemetrics, Lake Oswego, OR, USA), GraphPad Prism (GraphPad 
Software Inc., San Diego, CA, USA). 
STATISTICAL ANALYSIS 
Data are represented as mean values ± SEM. Two-tailed Student’s t-test was used to compare 
means; p < 0.05 was considered as statistically significant. 
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RESULTS 
GENETICS 
Genetic analysis was performed in all family members with the exception of the proband’s 
mother (Figure 4: I-2) where the carrier status was assumed from the fact that she died 
suddenly and unexpectedly at age 65 and that her husband did not carry the mutation, making 
her an obligate carrier. All clinically affected subjects (black circles/squares) were heterozygous 
carriers of a novel missense mutation in SCN5A, L1786Q. The mutated residue is highly 
conserved in voltage-gated Na+-channels with a conservation score of 1.014 as the original 
leucine is present in all known human SCN-proteins and, additionally, cross-species alignment 
of Nav1.5 reveals this leucine to be conserved beyond the mammalian kingdom (Figure 4). All 
clinically unaffected family members were found to have the wild-type with lysine at codon 
1786. 
CLINICAL PRESENTATION 
The proband (Figure 4: II-1) was resuscitated after a cardiac arrest at the age of 48 without any 
neurological deficits. The ECG revealed a clearly prolonged corrected QT interval of 0.48 sec, but 
without signs of an ST segment elevation pattern in the resting ECGs (Figure 5A). The proband 
was not inducible during an electrophysiology (EP) study using a standard protocol with up to 
three extra stimuli (minimum of 200 ms) and two basic drive cycle lengths (600 and 400 ms) 
from the right ventricular apex and outflow tract. Due to the cardiac arrest an ICD was 
implanted. Afterwards the proband received three appropriate shocks. During flecainide testing 
a coved type 1 ST segment elevation pattern was induced in lead V1. The brother (Figure 4: II-3) 
and a niece of the proband (Figure 4: III-3) also had clear QT prolongation without significant 
BrS pattern, but after flecainide provocation a clear BrS type 1 pattern were seen (Figure 5 E+F). 
The brother was asymptomatic but his daughter had experienced a single syncopal event at 
home following a tooth extraction with infection. Both were treated with a prophylactic ICD. 
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The brother's daughter did not experience any shocks during follow-up, whereas the brother 
has received two inappropriate shocks due to episodes of rapidly conducted atrial flutter.  
Figure 5C and D shows the recorded ICD electrogram (EGM) strips with two induction modes of 
arrhythmia: LQTS mode with short long short coupling sequence (Figure 5D) and BrS mode 
with a sudden premature beat eliciting the ventricular tachycardia (Figure 5C). 
WHOLE-CELL PATCH CLAMPING 
In order to investigate whether altered biophysical properties of the L1786Q Nav1.5 mutation 
can explain the observed patient phenotype voltage-clamp patch clamping was performed. 
Transient expression in HEK293 cells, followed by whole-cell patch clamping of the cells 
superfused with 37±1 °C in an extracellular solution containing 130 mM sodium, revealed fast 
activating and inactivating sodium currents for both WT and L1786Q Nav1.5 channels (Figure 2, 
Table 1). The applied voltage steps were preceded by a -120 mV step to insure full release from 
inactivation. The current peaks after 0.2-0.3 ms and is almost completely inactivated after 
5-10 ms. However, although the L1786Q mutant produced measurable current, the peak current 
was reduced approximately 3.5-fold as compared to WT Nav1.5 (Figure 2A,B,C). Analysis of 
steady-state activation and inactivation properties were performed to investigate whether these 
parameters could contributes to a reduced transient current, which could explain the BrS 
phenotype. The half steady-state activation potential was shifted from -28.5 mV to -13.3 mV 
(Figure 2E and Table 1), while the half steady-state inactivation potential was shifted from -67.0 
mV to -88.3 mV for WT and L1786Q, respectively (Figure 2C & Table 1). A positive shift in 
activation potential and a negative shift in inactivation potential will lead to a reduced 
availability of the channels, which will be consistent with a loss-of-function phenotype as 
observed in BrS. 
A biophysical explanation for the observed LQTS phenotype was addressed by analysing the late 
sodium current before and after addition of the sodium channel blocker TTX (Figure 3A). 50 μM 
TTX enforces an 80-90 % block of both WT and L1786Q Nav1.5 conducted peak Na+ current. 
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These experiments were conducted at 20±1 ºC to maintain a stable recording over the time 
course of TTX application. The TTX block revealed a three-fold increase in the sustained (INa, late) 
L1786Q current as compared to WT current when holding the potential at -20 mV (Figure 3B) in 
spite of the fact that L1786Q peak current was reduced drastically (Figure 3C). Further, as the 
membrane potential in a cardiomyocyte changes throughout the action potential the voltage 
dependence of the sustained current was investigated at different voltages (Figure 2F). The 
sustained current was recorded in sodium channel expressing cells at 37±1 ºC without TTX 
block. Mock transfected HEK293 cells do only show a very low sustained current (data not 
shown). Both wt and L1786Q channels have voltage dependent sustained currents with the 
highest current at the most negative values. The L1786Q sustained current (normalised to cell 
size) is significantly larger at -15 mV to -30 mV. Thus, the data reveal an increased sustained 
current for the L1786Q mutant channel which would be compatible with the observed LQTS 
phenotype. 
In summary, the electrophysiological investigations of the L1786Q Nav1.5 sodium channel 
provide evidence for the observed mixed phenotype of LQT and BrS. 
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DISCUSSION 
The main finding of the study is that the SCN5A L1786Q mutation leads to an overlap syndrome 
with combined LQTS and BrS, without any signs of ST elevation in the resting ECG. 
Today almost 100 mutations in SCN5A leading to BrS have been identified2, some of them with 
overlap syndromes between LQTS, CCD and sick sinus node syndromes17. As shown in Table 2 
only six other mutations have been clinically documented with comorbid BrS and LQTS. These 
six mutations span from the DII-III linker to the C-terminus.  
The SCN5A L1786Q mutation is located in the C-terminal end of SCN5A, in proximity to the 
E1784K and 1795insD mutations6, 18. The C-terminus is thought to have a role in stabilizing the 
inactivated channel, where it interacts with the intracellular linker between the DIII and DIV 
domain of SCN5A19. As demonstrated in Figure 2, the L1786Q mutation leads to a reduced peak 
sodium current, a leftwards shift in the inactivation curve, and a rightward shift in the activation 
curve, which would result in a reduced availability of functional sodium channels and thereby 
attribute to a loss of function phenotype. Whereas most wild type channels are released from 
inactivation at the resting membrane potential, the leftward shift in voltage dependent 
inactivation makes a large fraction of L1786Q channels inactivated at the resting potential, 
hence, not available for activation during the depolarizing process. The rightward shift in 
activation kinetics causes the sodium channels to activate at more positive potentials, which 
would also result in reduced peak sodium current. 
For the overlap mutations, encompassing a dual BrS and LQTS phenotype (Table 2), where 
electrophysiological analyses have been performed; a ubiquitous increase in late sodium 
current causes the LQTS phenotype, and a reduction of early sodium current causes the BrS 
phenotype. All but delK1500 had reduced peak sodium current, but the characterization of 
delK150020 was performed at a resting potential of -100 mV instead of at a more physiological 
value of -85 mV, masking the real effect on the peak sodium current difficult to quantify. 
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However, the large negative shift in the steady-state inactivation of delK1500 would lead to a 
net reduction of peak sodium current compatible with BrS.  
L1786Q provides a significant increase in the late sodium current. Interestingly, our analyses 
show a voltage dependency of this late current. The L1786Q late current is more pronounced at 
more negative voltages. These data thereby indicate that the sustained current has the largest 
impact in the late part of the phase II of the action potential, which gradually shows a declining 
potential, and may as well have an impact on phase III repolarisation. Such a relative increase in 
a depolarising current in the later part of the action potential will lead to a prolongation of the 
action potential duration and thereby prolonged QT interval.   
The clinical history of the proband indicates a malignant mutation with a course of aborted 
cardiac arrest and several occurrences of appropriate ICD shocks. According to the proposed 
diagnostic criteria, coved type ST segment elevation should be present in two right precordial 
leads (>2mm)21, 22 which was not fulfilled in the proband. However recently it has been shown 
that patients with only single lead coved ST elevation in lead V1 or V2 has similar prognosis as 
the classical pattern with elevation in two leads23.  
From the ICD print-outs (Figure 5 C+D), it is clear that there are two modes of initiating events. 
In Figure 5D a premature ventricular beat is followed by a post ectopic pause giving rise to the 
short-long-short sequence classical for LQTS, but in Figure 5C an early premature ventricular 
beat with a short coupling interval suggests a phase 2 re-entry arrhythmia24, a classical pattern 
for BrS. 
Treatment of overlap syndrome patients with combined LQTS+BrS impose a clinical problem. 
Beta blockers are effective in LQTS, but are known to increase ST elevation in BrS25. Sodium 
blocker may worsen BrS, although quinidine has been suggested to be useful in BrS due to the 
beneficial Ito blocking effect, but its IKr blocking abilities could induce further QT prolongation 
and torsades de pointes. Mexilitine has been shown not to unmask BrS in the overlap mutation 
SCN5A E1784K, but there are no reports of its continued use in these overlap syndrome 
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patients. A new alternative could be ranolazine, a late sodium current blocker, which may 
shorten the QT interval without affecting the peak current, hence should be beneficial for the 
LQTS without harm for the BrS part.  In the present family we decided to implant ICDs in all 
affected subjects even the asymptomatic subject because of the possible need for beta blocker 
treatment for the LQTS which may be harmful in BrS. Due to the limited evidence in overlap 
syndromes, it is unknown whether this will be justified in the future or reflect an overtreatment. 
The baseline T-wave morphology in the three patients is similar to late onset of a normal T-
wave pattern as described by Zhang et al26. This pattern is seen in less than 10% of all LQTS 
patients with SCN5A mutations, where late onset peaked/biphasic (53%) and asymmetrical 
peaked T-waves (12%) are more commonly seen26. Interestingly, the similar late onset of a 
normal T-wave pattern was also seen in two of the other combined BrS/LQTS mutations 
(E1784K18, 1795insD6), whereas in the other mutations published the baseline full 12 lead ECGs 
without flecainide were not revealed for evaluation. It is also noticeable that these three 
mutations with late onset normal pattern were C-terminal mutations in SCN5A. 
CONCLUSION 
We have described a case of combined BrS and LQTS in a patient with SCN5A L1786Q mutation 
where the typical BrS type 1 ST segment elevation was unmasked by flecainide provocation. Our 
results thereby confirm that a proportion of LQTS patients with a mutation in SCN5A may 
harbour a type 1 ECG Brugada ECG pattern when exposed to a class 1C antiarrhythmic. As the 
pharmacological treatment of BrS is different from that of LQTS, great care should be taken in 
defining the phenotype. It may be considered to let LQTS patients with SCN5A mutations 
undergo a sodium blocker provocation test. 
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FIGURE LEGENDS 
Figure 1. A) The homology alignment of the SCN5A sequences across eight species indicating 
the conservation of the mutated L1786 residue. Published LQTS and BrS mutations in this 
region are also indicated. B) This residue is also conserved in all types of human SCN alpha 
channels. 
 
Figure 2. Biophysical properties of wt vs. L1786Q Nav1.5 channels A) Voltage clamping of either 
WT or mutant (L1786Q) SCN5A transfected HEK293 cells at 37 ˚C. Representative traces. 
Increasing depolarizing voltages increasingly activates the Nav1.5 channels. However, as the 
reversal potential of sodium is approximately 50 mV, the peak current decreases at potentials 
higher than approximately – 20 mV. B) Current voltage (I-V) relationship. C) Normalized peak 
current at the maximum current recorded (wt; -20 mV, L1786Q; -5 mV). D) Steady-state 
inactivation as a function of voltage. E) Steady-state activation as a function of voltage. The 
Boltzmann curves were obtained as described under “Experimental Procedures”. The applied 
voltage protocols are shown in inserts. Arrows indicate were the current values are recorded. 
The left-ward shift in inactivation and the right-ward shift in activation of L1786Q compared to 
WT are both parameters that will reduce peak sodium current. F) Sustained current at different 
potentials recorded from wt and L1786Q expressing cells at 37 ˚C, normalised for cell size. *p < 
0.05, **p < 0.01, ***p < 0.001. 
 
Figure 3. A) The sustained current was addressed by depolarising the Nav1.5 transfected cells 
to -20 mV for 500 ms. Following the initial opening and inactivation of the sodium channel a 
small sustained current was observed (black traces). The part of this current conducted through 
the Nav1.5 channels was established by adding 50 μM tetrodotoxin (TTX) (red traces). B) 
Normalised TTX sensitive peak current. C) Normalised TTX sensitive sustained current. **p < 
0.01. [37] 
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Figure 4. Family pedigree, empty symbols (circles indicate females, and squares, males) depict 
unaffected members, filled symbols depict carriers of the SCN5A L1786Q mutation. The 
corrected QT interval (QTc) is shown above the gender symbol. The arrow indicates the 
proband (II-1). 
 
Figure 5. ECG and EGM traces: A) ECG trace from the proband with QT prolongation but 
without any signs of ST elevation. B) ECG trace from the proband during flecainide test with 
coved pattern. C) BrS pattern with ST elevation and a premature beat with a short coupling 
interval eliciting the arrhythmia. D) LQTS pattern of induction without ST elevation in EGM and 
a short-long-short coupling sequence. E) ECG trace from the proband’s brother (Figure 1: II-3) 
during flecainide testing. F) ECG trace from the proband’s niece (Figure 1: III-3) during 
flecainide testing. 
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Table 1. Biophysical properties of Ina recorded in HEK293 cells expressing WT Nav1.5 and 
L1786Q Nav1.5. *p<0.005, **p<0.005, ***p<0.001. 
 
 
Table 2. Electrophysiological characteristics of mutations associated with a mixed LQTS and 
BrS phenotype. 
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Figure 1.  
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Figure 2. 
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Figure 3. 
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Figure 4. 
 
Figure 5. 
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CHAPTER 6: ION CHANNEL GENES IMPLICATED IN STRUCTURAL 
HEART DISEASE 
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CHAPTER 7: DISCUSSION 
The societal significance of LQTS is emphasised by the prevalence of SCD among LQTS patients 
[38]. An appreciable portion of unexplained SCD in the young (individuals under 40-years-of-
age at the time of their death) and sudden infant death (SIDS) (the unexplained death of an 
infant under one-year-of-age) may be attributed to mutations in LQTS-causing genes [39-43]. 
Genetic testing for LQTS is a useful clinical tool in cases where family history is ambiguous or 
clinical data is missing (absent clinical data in SCD cases and absent or inconclusive QT interval 
prolongation on a single clinical test). Genetic testing in such cases may be useful in excluding 
one cause of sudden arrhythmia death syndrome (SADS) over another [44, 45]. Genetic testing 
is also useful in cases where the LQTS diagnosis is clear-cut and genetic diagnosis is used to 
inform patient management decisions [46-48]. Furthermore, cascade screening in family 
members can identify those relatives who are asymptomatic but are at increased risk of 
experiencing an arrhythmic event [44, 45, 49, 50]. It should be highlighted that genetic 
diagnosis of LQTS is complicated by variable penetrance, even among related individuals with 
the same genotype [51], and the possibility of compound and multiple mutations [1, 4, 6, 52-56]. 
Genetic screening of the five major LQTS-causing genes identified putative pathogenic 
mutations in approximately 75 to 80 % of cases [4, 57]. The missing mutations may be present 
in the unscreened LQTS-causing genes or in as yet unknown disease-causing genes. 
Furthermore, relevant mutations may be missed in the genes currently screened as a 
consequence of limitations of the sequencing methodologies applied i.e. intronic mutations 
which lie outside tested splice sites [58], and large deletion and duplication mutations [59, 60]. 
7.1 GENETIC AETIOLOGY OF LONG QT SYNDROME 
To establish a genetic diagnosis in a LQTS family is a complicated process [61] which often 
requires the collaboration of cardiologists, clinical geneticists and molecular geneticists. The 
studies reported here have limited genetic screening to the five most frequently implicated of 
the 13 known LQTS-causing genes (KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2). The relatively 
small sample size of these studies limits the possibility of identifying variants in genes that are 
rarely associated with LQTS [1]. However, these limited genetic screens have led to the 
identification of putative disease-causing mutations in 77 % and 82 % within the South African 
and Danish cohorts, respectively [4, 57]. This is comparable to those reported in other screening 
studies [54, 55, 62]. 
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LQTS is characteristically caused by “private” mutations (distinct genetic mutations which are 
observed in a single family) and screening of the two cohorts, presented here, identified many 
such mutations. However, the South African cohort included 23 founder families [63, 64] and 
screening of the Danish cohort identified several probands who carried identical mutations (five 
carriers of KCNH2:p.F29L and two carriers of KCNH2:p.K101E), these mutations were shown to 
be identical-by-descent in these probands and are thus the first Danish LQTS founder mutations 
to be described. Despite these founder mutations, the mutation spectrum in Denmark is similar 
to that found in other populations [1]. Whereas, the spectrum of mutations in the South African 
cohort is strongly skewed by the South African founder mutation (KCNQ1:p.A341V), which is 
carried by 52 % of the South African probands; in fact, even when accounting for the frequency 
of this mutation in the cohort, the mutation spectrum in South Africa is still very much skewed 
with respect to the number of KCNQ1 mutations. Furthermore, no SCN5A mutations were 
identified in this cohort. The South African LQTS cohort is strongly biased to individuals of 
European descent (~9 % of the total population of South Africa) and is not representative of all 
population groups in South Africa; this is despite extensive efforts to identify LQTS patients in 
the Black population. The “missed” LQTS mutations in the South African population may be 
present in a population group not well represented in the South African LQTS cohort. The 
Danish LQTS cohort, on the other hand, is representative of the Danish population. This 
difference in the representativity of the two cohorts might account for the differences in the 
mutation distribution observed within the two groups. 
We also determined that 4.5 % and 1.4 % of the South African and Danish cohorts were double 
or compound heterozygotes, respectively [4, 5]; this too is comparable to the frequency of 
double and compound heterozygotes seen in other populations [65]. The identification of 
double heterozygotes within the South African founder cohort emphasises the importance of 
performing comprehensive genetic screens on all LQTS probands, irrespective of the frequency 
of a founder mutation within the population; this is clinically relevant with respect to cascade 
screening within these families. Prior to preparing “Paper 2: Mutations in Danish Patients with 
Long QT Syndrome and Identification of a Large Founder Family with p.F29L in KCNH2” 
Grunnet et al. reported identifying a putative double heterozygote in this cohort 
(KCNQ1:p.R591H – KCNH2:p.R328C) [52]. Furthermore, analysis of the CAV3 gene in this cohort 
also identified another putative double heterozygote (KCNH2:p.I400N – CAV3:p.T78M) [6]. 
Functional assessment of these mutations and additional clinical investigations, particularly in 
family members who carry the mutations singularly, lead to the conclusion that the 
KCNQ1:p.R591H and the CAV3:p.T78M mutations were not contributing to disease in these 
families [6, 52]. This highlights the need for greater clinical and functional characterisation of 
novel mutations, particularly in cases of double and compound heterozygotes, as carriers of 
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multiple disease-causing mutations have been previously reported to exhibit more severe 
clinical phenotypes and a consequent increased need for clinical attention [66]. 
LQTS is characterised by broad clinical heterogeneity and incomplete penetrance which point to 
the existence of additional factors (genetic or environmental) that affect the QT interval and 
clinical presentation [63, 67, 68]. Several synonymous genetic variants, as well as frequently 
occurring non-synonymous genetic variants, were also identified in the South African cohort. 
Such polymorphisms are not disease causing, but they may modify the phenotype [1]. These 
potential forme fruste mutations, i.e. mutations that do not appear to cause disease in isolation, 
may affect cardiac repolarisation and thereby play a role in disease. A number of non-
synonymous polymorphisms have been reported to be associated with an effect in cardiac 
repolarisation currents [69]. KCNE1:p.D85N has been implicated in drug-induced LQTS [70] and 
KCNH2:p.R1047L has been reported to reduce IKr in a mammalian cell-based system [71]. 
Additionally, several polymorphisms have been reported to modify the functional effects of the 
LQTS-causing mutation which affects the South African founder group (KCNQ1:p.A341V) e.g. 
KCNH2:p.K897T [72] and several polymorphisms in NOS1AP [73]. 
While the pathophysiological effect of such genetic modifiers is not yet fully understood, it is 
hoped that, with the increasing application of next generation sequencing technologies in 
human genetics, it will become possible to identify novel causes and modifiers of diseases. 
7.2 DETERMINING THE PATHOGENICITY OF VARIANTS IN LQTS-CAUSING 
GENES 
Determining pathogenicity of genetic variants has changed dramatically during the course of 
these studies. The past decade has seen remarkable technical developments in the field of 
genetics along with an unprecedented ability to generate, store and evaluate large amounts of 
genetic data. There are currently over 6500 exomes available in the Exome Variant Server [74] 
and this growing number of well-documented exomes represents thousands of in silico control 
chromosomes, which subsequently increases the power to detect causal alleles, even when the 
number of available cases is limited as is frequently the case in LQTS. An assessment of SIDS 
causing mutations within the exome data collected in various population studies found that 
many of these variants occurred at a high frequency within these populations, thus bringing in 
to question the role that these variants may play in SIDS [75]. 
The sheer volume of publically available genetic data generated in both disease and normal 
populations necessitates that we, as medical geneticists, reassess genetic variants associated 
with our disease of interest. Variants of unknown significance (VUS), as well as variants which 
Stellenbosch University  http://scholar.sun.ac.za
  Page 179 
have been reported to be pathogenic, may be reclassified as genetic data is generated in other 
populations (a great deal of genetic data is Eurocentric) or clinical and functional data provide 
additional evidence supporting or opposing the initial characterisation of the variant. For 
instance, KCNH2:p.R176W was initially identified as a Finnish founder mutation [76] and a 
number of studies supported the pathogenicity of this variant [77-79], however, recently this 
variant has been determined to be a benign polymorphism [80, 81]. Another interesting 
example of how a variant might be reclassified as new data is generated is the KCNE1:p.D85N 
variant which poses an interesting challenge for medical geneticist working with LQTS. The 
KCNE1:p.D85N variant affects the IKs current, influences the QTc interval length [82] and is 
associated with drug-induced LQTS [70]. Furthermore, in 2009 a Japanese group reported that 
KCNE1:p.D85N was a disease-causing variant in Japan [83], a subsequent publication by this 
group reported that in a family carrying both KCNE1:p.D85N and KCNH2:p.E58K; individuals 
who were double heterozygotes experienced syncope while single mutation carriers were 
asymptomatic [84]. KCNE1:p.D85N occurs at MAF of 1.2 % in a population of European descent 
and a MAF of 0.2 % in a population of African descent [74]. While it is without doubt that this 
variant influences the QTc interval, it is unclear to what extent this variant is clinically relevant, 
but it is currently considered to be a low-penetrant causal variant or a modifying variant which 
is insufficient to cause disease in isolation. 
We should consider that the criteria that we traditionally apply when characterising genetic 
variants do not address questions of functional impairment or of clinical relevance directly 
(Figure 9). 
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Figure 9: A decision tree for the clinical interpretation of genetic variants. Types of evidence are shown in 
the box at the bottom left of the figure [85]. 
Generally, a genetic variant is predicted to be deleterious and thereby “likely-pathogenic” if it 
has an apparent functional effect i.e. it results in a frameshift, introduces a stop codon or 
disrupts correct splicing. Furthermore, a missense mutation is considered “probably-
pathogenic” if there is evidence that it has a deleterious effect on protein function. Such 
evidence includes a prediction of the severity of the amino acid substitution, the level of 
conservation of the affected amino acid residue and its segregation with disease in an affected 
kindred and/or its absence in > 100 control alleles. 
The argument for disease-causation is strengthened if the likely- or probably-pathogenic variant 
has been previously associated with disease. But the question of the clinical relevance of a 
putative mutation is difficult to address in diseases, like LQTS, which are characterised by 
“private” mutations, often found in small families. Functional assessments of putative disease-
causing mutations are rarely available and the clinical evidence for disease-causation is not 
readily available in the literature. Consequently, the classification of a genetic variant as disease-
causing is based on the inference of a few functional studies performed under in vitro 
conditions. Several prediction programs (e.g. SIFT, PANTHER, PolyPhen-2 and MutPred) have 
been developed to predict the likelihood that a given variant is pathogenic and so provide a 
means of distinguishing pathogenic mutations from rare, benign variants. These programs 
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typically apply algorithms which take into account evolutionary conservation of the primary 
structure of the protein as well as some measure of the effect a variant may have on the 
secondary structure. While these prediction programs require further validation and cannot, 
currently, substitute for a detailed understanding of the disease-mechanism several groups 
have determined that using the consensus predictions of several programs significantly 
improved the overall predictive value [86]. 
7.3 IDENTIFYING AND EVALUATING NEW GENETIC CAUSES OF LONG QT 
SYNDROME 
The two population-based genetic screening studies reported here [4, 5] were limited to 
screening the five most frequently implicated LQTS-causing genes (KCNQ1, KCNH2, SCN5A, 
KCNE1 and KCNE2). Using this limited approach, ~20% of LQTS cases are currently mutation-
negative. However, including more LQTS-causing genes in this standard screen may not be a 
cost effective approach to identifying the cause of disease in these cases, as the contribution of 
these additional genes is, in most cases, <1 % [1, 3]. 
7.3.1 COPY NUMBER VARIANTS 
While, unknown LQTS-causing genes could account for some of the mutation-negative LQTS-
cases observed here, a number of these cases might be attributable to exonic rearrangements in 
known LQTS-causing genes which are not detectable using standard PCR-based methods, which 
form the basis of most mutation screening methodologies.  
Copy number variants (CNVs) are defined as > 1Kb segments of DNA that differ in copy number 
between genomes. They encompass more DNA than single nucleotide polymorphisms (SNPs) 
within the genome and are a major source of genetic variation in humans [87]. CNVs can be 
limited to a single exon in a gene or include a contiguous set of genes [88]. Additionally, de novo 
locus-specific mutation rates for CNVs are between 2-4 orders of magnitude greater than those 
for SNPs [89]. 
As with other forms of genetic variation, CNVs may be of no significance to the phenotype or 
may be associated with clinical disease. Dosage sensitive genes may be susceptible to 
haploinsufficiency as a result of a CNV encompassing a whole gene, alternatively the deletion or 
duplication of an exon within a gene could result in the haploinsufficiency as a result of 
nonsense-mediated decay [90]. CNVs may exert their influence on phenotypic variability and 
disease susceptibility by modifying the expression of affected genes or by modifying the 
expression of genes close to the rearranged region [91]. Purifying selection has been reported to 
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act on several CNV loci, suggesting that rare variants potentially play a role in disease [92]. 
Furthermore, several whole genome assessments of structural variation have discovered CNVs 
in the genomic regions containing LQTS genes [93-100]. 
Using multiplex ligation-dependent probe amplification (MLPA) to assess a large portion of the 
Danish LQTS probands (91 %) lead to the identification of a large deletion affecting three exons 
in KCNQ1 [5]. Indicating that CNVs within KCNQ1 account for ~1.5 % of LQTS cases, greater than 
the occurrence of disease-causing mutations in KCNE1 or KCNE2 which are currently part of the 
standard LQTS screen [5]. Swedish and French studies identified a similar proportion of CNVs in 
their LQTS-cohorts [101, 102]. The significance of confirming these results using a second 
method cannot be overstated. An unpublished, study of 205 Danish LQTS probands identified 
CNV’s within the five LQTS genes at a similar frequency, however these findings could not be 
confirmed by long range PCR or Genome-Wide Human SNP Array 6.0 (Affymetrix) (Hedley et al. 
unpublished data) proving the MLPA discoveries to be false and highlighting the necessity of 
confirming MLPA results using a second method. 
7.3.2 ASSESSING THE EVIDENCE 
Screening of the CAV3 gene in Danish and British LQTS probands resulted in the identification of 
the c.233C>T; p.T78M variant in a Danish family, which was already known to be affected by the 
Kv11.1:p.I400N mutation [6]. Caveolin-3:p.T78M, has previously been associated with a number 
of diseases [103-106] including LQTS [107] and SIDS [108]. However, the association with 
disease, in all cases, was not clear-cut and, taken together, these data do not support the 
hypothesis that the caveolin-3:p.T78M mutation is pathogenic in the heterozygous state. 
Caveolin-3 is known to play a role in the availability of Kv11.1 at the cell membrane under 
hypokalaemic conditions [109]. This interdependence between hypokalaemia and caveolin-3 
function may explain the highly variable phenotypic expression of CAV3 mutations. 
Furthermore, in vitro studies showed that caveolin-3:p.T78M impairs the formation of caveolae 
in muscle cells [110-112] and disruption of caveolae might affect the beta-adrenergic 
responsiveness and the excitation–contraction coupling of cardiomyocytes [113-115]. 
Vaidyanathan et al. found that mutations in CAV3 (including p.T78M) significantly decreased IK1 
density [116]. It is interesting to speculate that the effect caveolin-3:p.T78M has on individual 
cardiac ion channels which form part of macromolecular complexes (containing several such 
ion channels) within caveolae [109, 117, 118] might produce a cumulative and possibly 
compensatory effect on the currents that make up the AP, making the effect of CAV3 mutations 
very difficult to assess using standard electrophysiological methods, which do not recapitulate 
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the physiological environment. The use of patient-specific induced pluripotent stem-cells [119] 
may be the key to resolving the clinically relevant effect CAV3 mutations have on the AP. 
While experimental evidence of the functional effect of an amino acid substitution may, in many 
cases, be lacking in silico prediction servers such as Polyphen-2 [120], SIFT [121] and 
MutationAssessor [122] can be used to assess the possible functional significance of an amino 
acid substitution. Using these three prediction servers, 80 % of LQTS mutations identified in the 
Danish LQTS cohort, with known in vitro deleterious effects, were considered to have a 
functional effect [5]. 
7.3.3 GENETIC VARIANTS OF MICRORNA GENES DO NOT PLAY A ROLE IN LONG QT 
SYNDROME  
Investigating genes involved in the regulation of cardiac ion channels is another strategy to 
identify the cause of disease in the ~10-20 % of LQTS cases which are currently considered 
mutation-negative. Animal models suggest that microRNAs (miRNAs) might be involved in the 
cardiac repolarisation [123] and a number of associations between SNPs in predicted miRNA 
binding sites on target mRNAs and phenotypic traits have previously been reported [124-127].  
Pri-miRNAs undergo a two-step cleavage process to produce a small (~22 nucleotide (nt)) 
mature miRNA. Seed regions (short 3-8 nt regions important for target specificity) of miRNA’s 
are highly conserved and SNPs are rarely seen in these regions. However, several reports 
provided evidence of clinically relevant phenotypes, in humans and mice, associated with 
miRNA seed region variants [128-130]. Variants outside of the seed region of mature miRNA 
have also been associated with clinical phenotypes; Dorn et al. demonstrated that a rare variant 
in mature MiR-499 protected against cardiomyopathy in a transgenic mouse model [131] and 
Ohanian et al. identified a genetic variant in mir-133a-2 which altered strand abundance 
resulting in an accumulation of the miRNA* (the degraded/passenger strand of miRNA duplex) 
strand in an atrial fibrillation patient [132]. Furthermore, several SNPs in pri-miRNA genes have 
been reported to affect processing and expression levels of mature miRNA [127, 133]. Amin et 
al. proposed that SNPs within miRNA binding sites may modify disease severity by virtue of the 
effect miRNAs have on translation of these transcripts [134]. We hypothesised that variants 
within the miRNA genes themselves may cause disease by disrupting the regulation of cardiac 
ion channels. 
We screened four miRNA genes in 125 Danish LQTS probands and found no putative disease-
causing mutations. However, we did not evaluate strand abundance and, consequently, we 
cannot conclude that none of the variants identified affect strand abundance [7]. 
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7.4 CARDIAC SODIUM CHANNEL OVERLAP SYNDROMES 
The SCN5A gene encodes the voltage gated α-subunit of the cardiac sodium channel, which 
controls the influx of Na+ into cardiomyocytes during the initial rapid depolarisation phase of 
the cardiac AP (phase 0). Mutations in SCN5A have been implicated in several cardiac diseases, 
including LQTS-type-3 (LQT3), BrS, cardiac conduction disease (CCD), sick sinus syndrome, 
atrial standstill, AF and DCM. The most common signs and symptoms of SCN5A-disease are 
depicted in Figure 10. 
 
Figure 10: A. Common signs and B. symptoms of SCN5A-disease. Figure adapted from [135] 
AF: atrial fibrillation, BrS: Brugada syndrome, CCD: cardiac conduction disease, DCM: dilated cardiomyopathy, 
LQTS: long QT syndrome, SCD: sudden cardiac death, SIDS: sudden infant death syndrome, SSS: sick sinus syndrome, 
SUD: sudden unexpected death. 
Initially, the various diseases associated with mutations in SCN5A were considered distinct 
clinical entities. However, reports of overlapping phenotypes, referred to as “cardiac sodium 
channel overlap syndromes”, in which clinical and biophysical properties of these diseases are 
mixed within a family or even within a single individual, negates this assertion [136]. 
The clinical and genetic diagnosis of these overlap syndromes is further complicated by variable 
disease expression within an affected family. Furthermore, the clinical management of cases 
with LQT3/BrS overlap syndrome is particularly problematic. Beta-blockers are effective in 
LQTS, but are known to increase ST elevation in BrS [137]. Sodium-blockers may worsen BrS, 
although quinidine has been suggested to be useful in BrS due to the beneficial Ito blocking 
effect, but its IKr blocking abilities would certainly induce further QT prolongation and torsades 
des pointes. New alternatives, such as ranolazine, a late sodium channel blocker, may be 
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effective in treating LQT3/BrS overlap patients. The clinical problems associated with treating 
these overlap patients highlights the significance of identifying them. 
We have reported the identification of a LQT3/BrS overlap syndrome, unmasked by flecainide 
testing, caused by the Nav1.5:p.L1786Q mutation [8] and we identified several known LQT3-
causing mutations in an early-onset lone AF cohort [9]. 
Flecainide testing of the Danish SCN5A-mutation-positive AF cohort did not reveal concealed 
BrS, as expected [138], however it did reveal a greater prolongation in QTc interval during 
flecainide testing than that expected for healthy individuals [139]. Indeed, three of the seven 
patients carrying LQT3-associated mutations had either a borderline prolonged QTc interval at 
baseline or a greater than expected prolongation of the QTc interval during flecainide testing 
[139]. 
It has been reported that LQTS mutation-carriers with QTc intervals <440ms have an increased 
risk for life-threatening cardiac events [1]. Consequently, we speculate that the early-onset AF 
patients carrying LQT3-associated mutations may have an increased risk of life-threatening 
arrhythmias. Furthermore, Lemoine et al. demonstrated atrial action potential prolongation, 
atrial EAD and triggered activity in a genetically modified animal model of human LQT3 [140]. 
Late onset of a normal T-wave pattern as described by Zhang et al. [141] was observed in the 
Nav1.5:p.L1786Q patients described here, as well as LQTS/BrS overlap patients carrying 
Nav1.5:p.E1784K [142] and Nav1.5:p.1795insD [143]. This pattern is uncommon in LQT3 
patients [141], and maybe indicative of LQT3/BrS overlap syndrome in individuals with SCN5A 
mutations. 
However improbable these cardiac sodium channel overlap syndromes seemed when first 
discovered they pose an interesting clinical problem in determining the best means of handling 
an SCN5A-mutation carrier. The association of SCN5A mutations with DCM [144, 145] suggests 
that the cardiac sodium channel may play a more complex role in cardiomyocyte function than 
previously thought. 
7.5 CHANNELOPATHY GENES CAUSE CARDIOMYOPATHY 
Patients with structural heart diseases such as hypertrophic cardiomyopathy (HCM) are at risk 
of developing life-threatening arrhythmias. In addition to the role SCN5A mutations play in 
structural heart disease cardiac ion channel β-subunits have been hypothesised to play a role in 
hypertrophy. A kcne2 null mouse model has been shown to develop cardiac hypertrophy as a 
consequence of hypothyroidism [146]. Furthermore, it has been suggested that mink (encoded 
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by KCNE1), through its interaction with telethonin [147], forms part of an “electro-mechanical 
feedback” system which links cardiomyocyte stretching to potassium flux. 
We analysed the KCNE genes (KCNE1, KCNE2, KCNE3, KCNE4 and KCNE1L) in a Danish HCM 
cohort. While variants in these genes have been associated with several inherited arrhythmic 
disorders such as LQTS [1, 2, 148, 149], AF [150] and BrS [151], the frequency of arrhythmia-
associated genetic variants was so low in the Danish HCM cohort, and did not convincingly differ 
from that of controls, that variants in these genes cannot explain the increased occurrence of 
arrhythmia in HCM [152]. However, the previously arrhythmia-associated variants 
minK:p.D85N [66, 153, 154] and MiRP1:p.T8A [155], as well as very rare genetic variants with 
likely functional significance, i.e. MiRP2:p.M1T and MiRP3:p.E141A, occurred more frequently in 
controls than in HCM patients. This suggests that neither KCNE1, despite its physical association 
with telethonin at the Z-disc [147], nor the other KCNE genes, are common causes of HCM. 
However, rare, but functionally significant variants in these genes may contribute to the risk of 
developing arrhythmias in the general population. 
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CHAPTER 8: CONCLUSION AND FUTURE DIRECTION 
There appears to be a lack of clinical relevance and biological significance in the criteria applied 
to the characterisation of disease-causing mutations. This was highlighted in our study of 
caveolin-3:p.T78M, which was purported to be a disease-causing variant in a number of 
diseases, and yet, when evaluating the evidence, we concluded that this variant is a rare 
polymorphism [6]. While we cannot exclude that caveolin-3:p.T78M modifies the disease 
phenotype, we must question the rationale for defining CAV3 as LQT9. 
Furthermore, using standard screening methods, the genetic cause of ~20 % of LQTS cases will 
remain unknown. In a bid to improve this detection rate, we employed several strategies to 
identify other genetic causes e.g. exon rearrangements in LQTS-causing genes, but unfortunately 
these were largely unsuccessful. The clinical significance and diagnostic utility of CNV screening 
in the LQTS genes remains unresolved. It would appear that CNV screening is more useful in a 
cohort of mutation-negative cases, but, as we are becoming increasingly aware, we cannot 
exclude the possibility of double and compound heterozygotes in LQTS. Indeed, the absence of 
CNV data is a limitation of all the genetic screening studies reported here. In addition, the 
assessment of miRNA genetic variation in LQTS patients in our study is limited by solely 
focusing on identifying genetic variation within the miRNA genes themselves and not assessing 
the MiR-1 and MiR-133A binding sites of putative target transcripts [7]. This decision was made 
because there is very little experimental evidence indicating which transcripts are targeted by 
specific miRNA’s. 
The study of SCN5A-disease and its characteristic overlap syndromes is highly clinically 
relevant, as patient management decisions are extremely complicated in these cases. A 
proportion of LQT3 SCN5A mutation-carriers might harbour a concealed BrS phenotype [8], and 
a proportion of AF SCN5A mutation-carriers could harbour a LQTS phenotype [9], along with the 
concomitant risk of arrhythmic events. Incorrect characterisation of these diseases and 
consequent incorrect treatment of these patients could inadvertently harm the patient and 
strategies should be in place to avoid this possibility. 
Significant progress has been made in understanding the genetic and biophysical aspects of 
LQTS. Despite this, establishing a genetic diagnosis in LQTS cases is still a complex matter as a 
consequence of the broad clinical heterogeneity, incomplete penetrance and the high 
prevalence of “private” mutations. To further complicate matters, the occurrence of double or 
compound heterozygotes and the involvement of modifying factors are not fully accounted for 
using current methodologies. This complexity raises a number of ethical issues; the clinical 
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relevance of a putative mutation is, in many instances, associated with a large degree of 
uncertainty and the implications of communicating this uncertainty have not been adequately 
evaluated [156]. Furthermore, the “duty-to-warn” at-risk relatives frequently outweighs the 
right of a family member “not-to-know” their mutation status [157]. 
The clinical service provided for these patients and their families could be strengthened by 
ensuring that the treating physicians are genetically-literate and work closely with genetic 
counsellors to best handle family data and disseminate genetic information into the family. As 
genetic analysis in LQTS should be reserved for patients with clinical signs and symptoms of 
disease followed by cascade screening of family members, it is necessary that these tests be 
ordered and interpreted by a specialist in cardiology and clinical genetics. However, clinical 
genetics is a fast evolving field; direct-to-consumer genetic screening in addition to limited 
interpretation and counselling services place a large burden on primary health physicians and 
nurses to keep abreast of the clinical application and interpretation of current genetic analyses 
[158]. Educating physicians and nurses in clinical genetics will relieve this burden and improve 
patient care. It is naïve to think, in this changing “landscape” of clinical genetics, that genetic 
testing can be entirely limited to specialised centres; in light of this, it is important to develop 
clear policies with respect to clinical utility and genetic counselling [159, 160]. Finally, it is very 
important that the clinical findings and the molecular data related to putative disease-causing 
mutations are made available to the scientific community, so that better interpretations of 
genetic data can be translated into clinical practice. This includes creating better access to 
negative data which is sorely missing from current scientific literature [10]. 
Several genetic variants within the known LQTS-causing genes have been found to be associated 
with acquired LQTS [70, 161], meaning that an improved understanding of the causes and 
mechanisms of congenital LQTS can be applied to the acquired LQTS. While the incidence of 
acquired LQTS is largely unknown, it is considered low for any one drug [162]. However, the 
significance for public health lies in the number and spectrum of drugs which potentially 
prolong the QT interval and the large number of patients receiving these drugs. These drugs are 
tightly regulated and in some cases have been withdrawn from the market [163]. 
The continued combination of population-based genetic studies with molecular and functional 
studies, along with the application of new methods to evaluate genetic causes and modifiers of 
disease, will help identify and categorise potentially relevant genetic variants. Additionally, a re-
evaluation of the current criteria applied to characterise a disease-causing mutation and the 
development of improved in silico tools to better predict the consequence of novel mutations 
will facilitate better risk stratification in carriers of LQTS-causing mutations. Next generation 
sequencing (NGS) technologies hold great promise in the identification of novel genetic factors 
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of disease. Ultimately, clinical genetic laboratories will increase the success rate of genetic 
screens through the use whole genome/exome sequencing. In addition to improving screening 
outcomes and generating insight into disease mechanisms, NGS generates vast amounts of data 
which requires improved bioinformatics and data-handling solutions as well as clear guideline 
with respect to informing patients and the role of physicians and geneticists in this process. 
Furthermore, the collection of whole genome/whole exome data on large families, like the South 
African founder families, would, in the future, provide the possibility to identify possible 
second-order interactions between causal and modifying genes. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 190 
CHAPTER 9: REFERENCES 
1. Hedley PL, Jorgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, 
Corfield VA, Christiansen M: The genetic basis of long QT and short QT syndromes: a 
mutation update. Hum Mutat 2009, 30:1486-1511. 
2. Hedley PL, Jorgensen P, Schlamowitz S, Moolman-Smook J, Kanters JK, Corfield VA, 
Christiansen M: The genetic basis of Brugada syndrome: a mutation update. Hum Mutat 
2009, 30:1256-1266. 
3. Christiansen M, Hedley PL: Long QT testing: implications for complex diagnosis in 
personalized medicine. Personalized Medicine 2010, 7:125-127. 
4. Hedley PL, Durrheim GA, Hendricks F, Goosen A, Jespersgaard C, Stovring B, Pham TT, 
Christiansen M, Brink PA, Corfield VA: Long QT syndrome in South Africa : the results of 
comprehensive genetic screening : cardiovascular topic. Cardiovascular Journal Of Africa 
2013, 24:231-237. 
5. Christiansen M, Hedley PL, Theilade J, Stoevring B, Leren TP, Eschen O, K.M. S: Mutations in 
Danish patients with long QT syndrome and identification of a large founder family with 
p.F29L in KCNH2. BMC Medical Genetics 2013, submitted. 
6. Hedley PL, Kanters JK, Dembic M, Jespersen T, Skibsbye L, Aidt FH, Eschen O, Graff C, Behr 
ER, Schlamowitz S, et al: The Role of CAV3 in Long QT Syndrome: Clinical and Functional 
Assessment of a Caveolin-3/Kv11.1 Double Heterozygote Versus Caveolin-3 Single 
Heterozygote. Circ Cardiovasc Genet 2013, 6:452-461. 
7. Hedley PL, Carlsen AL, Christiansen K, Kanters JK, Behr ER, Corfield VA, Christiansen M: 
MicroRNA in long QT syndrome. Scandinavian Journal of Clinical & Laboratory Investigation 
2013, Submitted. 
8. Kanters JK, Yuan L, Hedley PL, Stoevring B, Joens C, Bloch-Thomsen PE, Grunnet M, 
Christiansen M, Jespersen T: Flecainide provocation reveals concealed Brugada syndrome 
in a long QT syndrome family with a novel L1786Q mutation in SCN5A. Circulation Journal 
2013, Submitted. 
9. Olesen MS, Yuan L, Liang B, Holst AG, Nielsen N, Nielsen JB, Hedley PL, Christiansen M, 
Olesen S-P, Haunsø S: High Prevalence of Long QT Syndrome–Associated SCN5A Variants in 
Patients With Early-Onset Lone Atrial FibrillationClinical Perspective. Circ Cardiovasc Genet 
2012, 5:450-459. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 191 
10. Hedley PL, Haundrup O, Andersen PS, Aidt FH, Jensen M, Moolman-Smook JC, Bundgaard H, 
Christiansen M: The KCNE genes in hypertrophic cardiomyopathy: a candidate gene study. 
J Negat Results Biomed 2011, 10:12. 
11. McCain ML, Lee H, Aratyn-Schaus Y, Kleber AG, Parker KK: Cooperative coupling of cell-
matrix and cell-cell adhesions in cardiac muscle. Proc Natl Acad Sci U S A 2012, 109:9881-
9886. 
12. Severs NJ: The cardiac muscle cell. Bioessays 2000, 22:188-199. 
13. Jongbloed MR, Vicente Steijn R, Hahurij ND, Kelder TP, Schalij MJ, Gittenberger-de Groot AC, 
Blom NA: Normal and abnormal development of the cardiac conduction system; 
implications for conduction and rhythm disorders in the child and adult. Differentiation 
2012, 84:131-148. 
14. Braam SR, Passier R, Mummery CL: Cardiomyocytes from human pluripotent stem cells in 
regenerative medicine and drug discovery. Trends Pharmacol Sci 2009, 30:536-545. 
15. Durrer D, van Dam RT, Freud GE, Janse MJ, Meijler FL, Arzbaecher RC: Total excitation of the 
isolated human heart. Circulation 1970, 41:899-912. 
16. Lazzara R: Arrhythmia mechanisms in the new millennium. J Interv Card Electrophysiol 
2001, 5:133-135. 
17. Wellens HJ: Cardiac arrhythmias: the quest for a cure: a historical perspective. J Am Coll 
Cardiol 2004, 44:1155-1163. 
18. Chakrabarti S, Stuart AG: Understanding cardiac arrhythmias. Arch Dis Child 2005, 90:1086-
1090. 
19. Tan HL, Hou CJ, Lauer MR, Sung RJ: Electrophysiologic mechanisms of the long QT interval 
syndromes and torsade de pointes. Ann Intern Med 1995, 122:701-714. 
20. Bazett HC: The time relations of the blood-pressure changes after excision of the adrenal 
glands, with some observations on blood volume changes. J Physiol 1920, 53:320-339. 
21. Keating MT, Sanguinetti MC: Molecular and cellular mechanisms of cardiac arrhythmias. 
Cell 2001, 104:569-580. 
22. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, Haase N, Ho M, Howard V, 
Kissela B, et al: Heart disease and stroke statistics--2007 update: a report from the 
American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 
Circulation 2007, 115:e69-171. 
23. Nattel S: New ideas about atrial fibrillation 50 years on. Nature 2002, 415:219-226. 
24. Zipes DP, Wellens HJ: Sudden cardiac death. Circulation 1998, 98:2334-2351. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 192 
25. Josephson M, Wellens HJ: Implantable defibrillators and sudden cardiac death. Circulation 
2004, 109:2685-2691. 
26. Fishman GI, Chugh SS, Dimarco JP, Albert CM, Anderson ME, Bonow RO, Buxton AE, Chen PS, 
Estes M, Jouven X, et al: Sudden cardiac death prediction and prevention: report from a 
National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 
2010, 122:2335-2348. 
27. Kong MH, Fonarow GC, Peterson ED, Curtis AB, Hernandez AF, Sanders GD, Thomas KL, 
Hayes DL, Al-Khatib SM: Systematic review of the incidence of sudden cardiac death in the 
United States. J Am Coll Cardiol 2011, 57:794-801. 
28. Deo R, Albert CM: Epidemiology and genetics of sudden cardiac death. Circulation 2012, 
125:620-637. 
29. Rubart M, Zipes DP: Mechanisms of sudden cardiac death. J Clin Invest 2005, 115:2305-
2315. 
30. Huikuri HV, Castellanos A, Myerburg RJ: Sudden death due to cardiac arrhythmias. N Engl J 
Med 2001, 345:1473-1482. 
31. Adamson PB, Barr RC, Callans DJ, Chen PS, Lathrop DA, Makielski JC, Nerbonne JM, Nuss HB, 
Olgin JE, Przywara DA, et al: The perplexing complexity of cardiac arrhythmias: beyond 
electrical remodeling. Heart Rhythm 2005, 2:650-659. 
32. Mohler PJ, Splawski I, Napolitano C, Bottelli G, Sharpe L, Timothy K, Priori SG, Keating MT, 
Bennett V: A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl 
Acad Sci U S A 2004, 101:9137-9142. 
33. Priori SG, Barhanin J, Hauer RN, Haverkamp W, Jongsma HJ, Kleber AG, McKenna WJ, Roden 
DM, Rudy Y, Schwartz K, et al: Genetic and molecular basis of cardiac arrhythmias; impact 
on clinical management. Study group on molecular basis of arrhythmias of the working 
group on arrhythmias of the european society of cardiology. Eur Heart J 1999, 20:174-195. 
34. Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, 
Zareba W, American Heart Association Acute Cardiac Care Committee of the Council on 
Clinical Cardiology tCoCN, the American College of Cardiology F: Prevention of torsade de 
pointes in hospital settings: a scientific statement from the American Heart Association 
and the American College of Cardiology Foundation. Circulation 2010, 121:1047-1060. 
35. Grilo LS, Carrupt PA, Abriel H: Stereoselective Inhibition of the hERG1 Potassium Channel. 
Front Pharmacol 2010, 1:137. 
36. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM: What clinicians should know about the 
QT interval. JAMA 2003, 289:2120-2127. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 193 
37. Shewan LG, Coats AJS: Ethics in the authorship and publishing of scientific artcles. 
International Journal of Cardiology 2010. 
38. Modell SM, Lehmann MH: The long QT syndrome family of cardiac ion channelopathies: a 
HuGE review. Genet Med 2006, 8:143-155. 
39. Goldenberg I, Moss AJ, Peterson DR, McNitt S, Zareba W, Andrews ML, Robinson JL, Locati 
EH, Ackerman MJ, Benhorin J, et al: Risk factors for aborted cardiac arrest and sudden 
cardiac death in children with the congenital long-QT syndrome. Circulation 2008, 
117:2184-2191. 
40. Moss AJ, Goldenberg I: Importance of Knowing the Genotype and the Specific Mutation 
When Managing Patients with Long QT Syndrome. Circ Arrhythm Electrophysiol 2008, 
1:213-226; discussion 226. 
41. Hobbs JB, Peterson DR, Moss AJ, McNitt S, Zareba W, Goldenberg I, Qi M, Robinson JL, Sauer 
AJ, Ackerman MJ, et al: Risk of aborted cardiac arrest or sudden cardiac death during 
adolescence in the long-QT syndrome. JAMA 2006, 296:1249-1254. 
42. Ackerman MJ: Cardiac causes of sudden unexpected death in children and their 
relationship to seizures and syncope: genetic testing for cardiac electropathies. Semin 
Pediatr Neurol 2005, 12:52-58. 
43. Bastiaenen R, Behr ER: Sudden death and ion channel disease: pathophysiology and 
implications for management. Heart 2011, 97:1365-1372. 
44. Tester DJ, Ackerman MJ: Genetic testing for potentially lethal, highly treatable inherited 
cardiomyopathies/channelopathies in clinical practice. Circulation 2011, 123:1021-1037. 
45. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob 
M, Hamilton R, et al: HRS/EHRA expert consensus statement on the state of genetic testing 
for the channelopathies and cardiomyopathies this document was developed as a 
partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm 
Association (EHRA). Heart Rhythm 2011, 8:1308-1339. 
46. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, 
Priori SG, Napolitano C, et al: Effectiveness and limitations of beta-blocker therapy in 
congenital long-QT syndrome. Circulation 2000, 101:616-623. 
47. Goldenberg I, Moss AJ, Bradley J, Polonsky S, Peterson DR, McNitt S, Zareba W, Andrews ML, 
Robinson JL, Ackerman MJ, et al: Long-QT syndrome after age 40. Circulation 2008, 
117:2192-2201. 
48. Liu JF, Jons C, Moss AJ, McNitt S, Peterson DR, Qi M, Zareba W, Robinson JL, Barsheshet A, 
Ackerman MJ, et al: Risk factors for recurrent syncope and subsequent fatal or near-fatal 
Stellenbosch University  http://scholar.sun.ac.za
  Page 194 
events in children and adolescents with long QT syndrome. J Am Coll Cardiol 2011, 57:941-
950. 
49. Heart Rhythm UKFSDSSDG: Clinical indications for genetic testing in familial sudden cardiac 
death syndromes: an HRUK position statement. Heart 2008, 94:502-507. 
50. Hofman N, Tan HL, Alders M, van Langen IM, Wilde AA: Active cascade screening in primary 
inherited arrhythmia syndromes: does it lead to prophylactic treatment? J Am Coll Cardiol 
2010, 55:2570-2576. 
51. Kaufman ES, Priori SG, Napolitano C, Schwartz PJ, Iyengar S, Elston RC, Schnell AH, Gorodeski 
EZ, Rammohan G, Bahhur NO, et al: Electrocardiographic prediction of abnormal genotype 
in congenital long QT syndrome: experience in 101 related family members. J Cardiovasc 
Electrophysiol 2001, 12:455-461. 
52. Grunnet M, Behr ER, Calloe K, Hofman-Bang J, Till J, Christiansen M, McKenna WJ, Olesen SP, 
Schmitt N: Functional assessment of compound mutations in the KCNQ1 and KCNH2 genes 
associated with long QT syndrome. Heart Rhythm 2005, 2:1238-1249. 
53. Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, Wilde AA, 
Ackerman MJ: Spectrum and prevalence of mutations from the first 2,500 consecutive 
unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart 
Rhythm 2009, 6:1297-1303. 
54. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, Bottelli G, Cerrone M, 
Leonardi S: Genetic testing in the long QT syndrome: development and validation of an 
efficient approach to genotyping in clinical practice. JAMA 2005, 294:2975-2980. 
55. Tester DJ, Will ML, Haglund CM, Ackerman MJ: Compendium of cardiac channel mutations 
in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart 
Rhythm 2005, 2:507-517. 
56. Wilde AA: Long QT syndrome: a double hit hurts more. Heart Rhythm 2010, 7:1419-1420. 
57. Theilade J, Kanters J, Henriksen FL, Gilsa-Hansen M, Svendsen JH, Eschen O, Toft E, Reimers 
JI, Tybjaerg-Hansen A, Christiansen M, et al: Cascade Screening in Families with Inherited 
Cardiac Diseases Driven by Cardiologists: Feasibility and Nationwide Outcome in Long QT 
Syndrome. Cardiology 2013, 126:131-137. 
58. Vincent GM, Zhang L: The role of genotyping in diagnosing cardiac channelopathies : 
progress to date. Mol Diagn 2005, 9:105-118. 
59. Koopmann TT, Alders M, Jongbloed RJ, Guerrero S, Mannens MM, Wilde AA, Bezzina CR: 
Long QT syndrome caused by a large duplication in the KCNH2 (HERG) gene undetectable 
Stellenbosch University  http://scholar.sun.ac.za
  Page 195 
by current polymerase chain reaction-based exon-scanning methodologies. Heart Rhythm 
2006, 3:52-55. 
60. Eddy CA, MacCormick JM, Chung SK, Crawford JR, Love DR, Rees MI, Skinner JR, Shelling AN: 
Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients 
with long QT syndrome. Heart Rhythm 2008, 5:1275-1281. 
61. Johnson JN, Ackerman MJ: QTc: how long is too long? Br J Sports Med 2009, 43:657-662. 
62. Berge KE, Haugaa KH, Fruh A, Anfinsen OG, Gjesdal K, Siem G, Oyen N, Greve G, Carlsson A, 
Rognum TO, et al: Molecular genetic analysis of long QT syndrome in Norway indicating a 
high prevalence of heterozygous mutation carriers. Scand J Clin Lab Invest 2008, 68:362-
368. 
63. Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, Heradien M, Geldenhuys G, 
Vanoli E, Bacchini S: Phenotypic variability and unusual clinical severity of congenital long-
QT syndrome in a founder population. Circulation 2005, 112:2602-2610. 
64. de Jager T, Corbett CH, Badenhorst JC, Brink PA, Corfield VA: Evidence of a long QT founder 
gene with varying phenotypic expression in South African families. J Med Genet 1996, 
33:567-573. 
65. Zaklyazminskaya EV, Abriel H: Prevalence of Significant Genetic Variants in Congenital Long 
QT Syndrome is Largely Underestimated. Front Pharmacol 2012, 3:72. 
66. Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC: Compound mutations: 
a common cause of severe long-QT syndrome. Circulation 2004, 109:1834-1841. 
67. Crotti L, Spazzolini C, Schwartz PJ, Shimizu W, Denjoy I, Schulze-Bahr E, Zaklyazminskaya EV, 
Swan H, Ackerman MJ, Moss AJ, et al: The common long-QT syndrome mutation 
KCNQ1/A341V causes unusually severe clinical manifestations in patients with different 
ethnic backgrounds: toward a mutation-specific risk stratification. Circulation 2007, 
116:2366-2375. 
68. Priori SG, Napolitano C, Schwartz PJ: Low penetrance in the long-QT syndrome: clinical 
impact. Circulation 1999, 99:529-533. 
69. Kaab S, Schulze-Bahr E: Susceptibility genes and modifiers for cardiac arrhythmias. 
Cardiovasc Res 2005, 67:397-413. 
70. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-
Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J: Genetic variations of KCNQ1, 
KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 
(Berl) 2004, 82:182-188. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 196 
71. Laohakunakorn P, Benson DW, Yang P, Yang T, Roden DM, Kugler JD: Bidirectional 
ventricular tachycardia and channelopathy. Am J Cardiol 2003, 92:991-995. 
72. Crotti L, Lundquist AL, Insolia R, Pedrazzini M, Ferrandi C, De Ferrari GM, Vicentini A, Yang P, 
Roden DM, George AL, Jr., Schwartz PJ: KCNH2-K897T is a genetic modifier of latent 
congenital long-QT syndrome. Circulation 2005, 112:1251-1258. 
73. Crotti L, Monti MC, Insolia R, Peljto A, Goosen A, Brink PA, Greenberg DA, Schwartz PJ, 
George AL, Jr.: NOS1AP is a genetic modifier of the long-QT syndrome. Circulation 2009, 
120:1657-1663. 
74. (EVS) EVS: NHLBI GO Exome Sequencing Project (ESP). Seattle, WA. 
75. Andreasen C, Refsgaard L, Nielsen JB, Sajadieh A, Winkel BG, Tfelt-Hansen J, Haunso S, Holst 
AG, Svendsen JH, Olesen MS: Mutations in Genes Encoding Cardiac Ion Channels Previously 
Associated With Sudden Infant Death Syndrome (SIDS) Are Present With High Frequency in 
New Exome Data. Can J Cardiol 2013, 29:1104-1109. 
76. Marjamaa A, Salomaa V, Newton-Cheh C, Porthan K, Reunanen A, Karanko H, Jula A, 
Lahermo P, Vaananen H, Toivonen L, et al: High prevalence of four long QT syndrome 
founder mutations in the Finnish population. Ann Med 2009, 41:234-240. 
77. Fodstad H, Bendahhou S, Rougier JS, Laitinen-Forsblom PJ, Barhanin J, Abriel H, Schild L, 
Kontula K, Swan H: Molecular characterization of two founder mutations causing long QT 
syndrome and identification of compound heterozygous patients. Ann Med 2006, 38:294-
304. 
78. Lahti AL, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M, Kerkela E, Hyttinen J, 
Kontula K, Swan H, Conklin BR, et al: Model for long QT syndrome type 2 using human iPS 
cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 2012, 
5:220-230. 
79. Obeyesekere MN, Sy RW, Klein GJ, Gula LJ, Modi S, Conacher S, Leong-Sit P, Skanes AC, Yee 
R, Krahn AD: End-recovery QTc: a useful metric for assessing genetic variants of unknown 
significance in long-QT syndrome. J Cardiovasc Electrophysiol 2012, 23:637-642. 
80. Giudicessi JR, Kapplinger JD, Tester DJ, Alders M, Salisbury BA, Wilde AA, Ackerman MJ: 
Phylogenetic and physicochemical analyses enhance the classification of rare 
nonsynonymous single nucleotide variants in type 1 and 2 long-QT syndrome. Circ 
Cardiovasc Genet 2012, 5:519-528. 
81. Jou CJ, Barnett SM, Bian JT, Weng HC, Sheng X, Tristani-Firouzi M: An in vivo cardiac assay to 
determine the functional consequences of putative long QT syndrome mutations. Circ Res 
2013, 112:826-830. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 197 
82. Gouas L, Nicaud V, Berthet M, Forhan A, Tiret L, Balkau B, Guicheney P, Group DESIRS: 
Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length 
in a healthy population. Eur J Hum Genet 2005, 13:1213-1222. 
83. Nishio Y, Makiyama T, Itoh H, Sakaguchi T, Ohno S, Gong YZ, Yamamoto S, Ozawa T, Ding 
WG, Toyoda F, et al: D85N, a KCNE1 polymorphism, is a disease-causing gene variant in 
long QT syndrome. J Am Coll Cardiol 2009, 54:812-819. 
84. Hasegawa K, Ohno S, Itoh H, Makiyama T, Aiba T, Nakano Y, Shimizu W, Matsuura H, Makita 
N, Horie M: A rare KCNE1 polymorphism, D85N, as a genetic modifier of long QT syndrome. 
Journal of Arrhythmia 2013. 
85. Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, Lyon E, Ward BE, Molecular 
Subcommittee of the ALQAC: ACMG recommendations for standards for interpretation and 
reporting of sequence variations: Revisions 2007. Genet Med 2008, 10:294-300. 
86. Ohanian M, Otway R, Fatkin D: Heuristic methods for finding pathogenic variants in gene 
coding sequences. J Am Heart Assoc 2012, 1:e002642. 
87. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, 
Denisov G, et al: The Diploid Genome Sequence of an Individual Human. PLoS Biol 2007, 
5:e254. 
88. Zhang F, Gu W, Hurles ME, Lupski JR: Copy number variation in human health, disease, and 
evolution. Annu Rev Genomics Hum Genet 2009, 10:451-481. 
89. Lupski JR: Genomic rearrangements and sporadic disease. Nat Genet 2007, 39:S43-47. 
90. Chan D, Weng YM, Graham HK, Sillence DO, Bateman JF: A nonsense mutation in the 
carboxyl-terminal domain of type X collagen causes haploinsufficiency in schmid 
metaphyseal chondrodysplasia. J Clin Invest 1998, 101:1490-1499. 
91. Henrichsen CN, Chaignat E, Reymond A: Copy number variants, diseases and gene 
expression. Hum Mol Genet 2009, 18:R1-8. 
92. Conrad DF, Pinto D, Redon R, Feuk L, Gokcumen O, Zhang Y, Aerts J, Andrews TD, Barnes C, 
Campbell P, et al: Origins and functional impact of copy number variation in the human 
genome. Nature 2010, 464:704-712. 
93. Jakobsson M, Scholz SW, Scheet P, Gibbs JR, VanLiere JM, Fung HC, Szpiech ZA, Degnan JH, 
Wang K, Guerreiro R, et al: Genotype, haplotype and copy-number variation in worldwide 
human populations. Nature 2008, 451:998-1003. 
94. Kidd JM, Cooper GM, Donahue WF, Hayden HS, Sampas N, Graves T, Hansen N, Teague B, 
Alkan C, Antonacci F, et al: Mapping and sequencing of structural variation from eight 
human genomes. Nature 2008, 453:56-64. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 198 
95. Matsuzaki H, Wang PH, Hu J, Rava R, Fu GK: High resolution discovery and confirmation of 
copy number variants in 90 Yoruba Nigerians. Genome Biol 2009, 10:R125. 
96. Pang AW, MacDonald JR, Pinto D, Wei J, Rafiq MA, Conrad DF, Park H, Hurles ME, Lee C, 
Venter JC, et al: Towards a comprehensive structural variation map of an individual human 
genome. Genome Biol 2010, 11:14. 
97. Perry GH, Ben-Dor A, Tsalenko A, Sampas N, Rodriguez-Revenga L, Tran CW, Scheffer A, 
Steinfeld I, Tsang P, Yamada NA, et al: The fine-scale and complex architecture of human 
copy-number variation. Am J Hum Genet 2008, 82:685-695. 
98. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson 
AR, Chen W, et al: Global variation in copy number in the human genome. Nature 2006, 
444:444-454. 
99. Shaikh TH, Gai X, Perin JC, Glessner JT, Xie H, Murphy K, O'Hara R, Casalunovo T, Conlin LK, 
D'Arcy M, et al: High-resolution mapping and analysis of copy number variations in the 
human genome: a data resource for clinical and research applications. Genome Res 2009, 
19:1682-1690. 
100. Zogopoulos G, Ha KC, Naqib F, Moore S, Kim H, Montpetit A, Robidoux F, Laflamme P, 
Cotterchio M, Greenwood C, et al: Germ-line DNA copy number variation frequencies in a 
large North American population. Hum Genet 2007, 122:345-353. 
101. Stattin EL, Bostrom IM, Winbo A, Cederquist K, Jonasson J, Jonsson BA, Diamant UB, Jensen 
SM, Rydberg A, Norberg A: Founder mutations characterise the mutation panorama in 200 
Swedish index cases referred for Long QT syndrome genetic testing. BMC Cardiovasc Disord 
2012, 12:95. 
102. Barc J, Briec F, Schmitt S, Kyndt F, Le Cunff M, Baron E, Vieyres C, Sacher F, Redon R, Le 
Caignec C, et al: Screening for copy number variation in genes associated with the long QT 
syndrome: clinical relevance. J Am Coll Cardiol 2011, 57:40-47. 
103. Reijneveld JC, Ginjaar IB, Frankhuizen WS, Notermans NC: CAV3 gene mutation analysis in 
patients with idiopathic hyper-CK-emia. Muscle Nerve 2006, 34:656-658. 
104. Ricci G, Scionti I, Ali G, Volpi L, Zampa V, Fanin M, Angelini C, Politano L, Tupler R, Siciliano G: 
Rippling muscle disease and facioscapulohumeral dystrophy-like phenotype in a patient 
carrying a heterozygous CAV3 T78M mutation and a D4Z4 partial deletion: Further 
evidence for "double trouble" overlapping syndromes. Neuromuscul Disord 2012, 22:534-
540. 
105. Spadafora P, Liguori M, Andreoli V, Quattrone A, Gambardella A: CAV3 T78M mutation as 
polymorphic variant in South Italy. Neuromuscul Disord 2012, 22:669-670. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 199 
106. Traverso M, Bruno C, Broccolini A, Sotgia F, Donati MA, Assereto S, Gazzerro E, Lo Monaco 
M, Modoni A, D'Amico A, et al: Truncation of Caveolin-3 causes autosomal-recessive 
Rippling Muscle Disease. J Neurol Neurosurg Psychiatry 2008, 79:735-737. 
107. Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, Taylor EW, Tester DJ, Balijepalli RC, 
Foell JD, Li Z, et al: Mutant caveolin-3 induces persistent late sodium current and is 
associated with long-QT syndrome. Circulation 2006, 114:2104-2112. 
108. Cronk LB, Ye B, Kaku T, Tester DJ, Vatta M, Makielski JC, Ackerman MJ: Novel mechanism for 
sudden infant death syndrome: persistent late sodium current secondary to mutations in 
caveolin-3. Heart Rhythm 2007, 4:161-166. 
109. Massaeli H, Sun T, Li X, Shallow H, Wu J, Xu J, Li W, Hanson C, Guo J, Zhang S: Involvement of 
caveolin in low K+-induced endocytic degradation of cell-surface human ether-a-go-go-
related gene (hERG) channels. J Biol Chem 2010, 285:27259-27264. 
110. Das K, Lewis RY, Scherer PE, Lisanti MP: The membrane-spanning domains of caveolins-1 
and -2 mediate the formation of caveolin hetero-oligomers. Implications for the assembly 
of caveolae membranes in vivo. J Biol Chem 1999, 274:18721-18728. 
111. Parton RG: Caveolae and caveolins. Curr Opin Cell Biol 1996, 8:542-548. 
112. Schlegel A, Lisanti MP: A molecular dissection of caveolin-1 membrane attachment and 
oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate 
membrane binding and oligomer/oligomer interactions in vivo. J Biol Chem 2000, 
275:21605-21617. 
113. Balijepalli RC, Foell JD, Hall DD, Hell JW, Kamp TJ: Localization of cardiac L-type Ca(2+) 
channels to a caveolar macromolecular signaling complex is required for beta(2)-
adrenergic regulation. Proc Natl Acad Sci U S A 2006, 103:7500-7505. 
114. Barbuti A, Terragni B, Brioschi C, DiFrancesco D: Localization of f-channels to caveolae 
mediates specific beta2-adrenergic receptor modulation of rate in sinoatrial myocytes. J 
Mol Cell Cardiol 2007, 42:71-78. 
115. Calaghan S, White E: Caveolae modulate excitation-contraction coupling and beta2-
adrenergic signalling in adult rat ventricular myocytes. Cardiovasc Res 2006, 69:816-824. 
116. Vaidyanathan R, Vega AL, Song C, Zhou Q, Tan B, Berger S, Makielski JC, Eckhardt LL: The 
interaction of caveolin 3 protein with the potassium inward rectifier channel Kir2.1: 
physiology and pathology related to long qt syndrome 9 (LQT9). J Biol Chem 2013, 
288:17472-17480. 
117. Balijepalli RC, Kamp TJ: Caveolae, ion channels and cardiac arrhythmias. Prog Biophys Mol 
Biol 2008, 98:149-160. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 200 
118. Maguy A, Hebert TE, Nattel S: Involvement of lipid rafts and caveolae in cardiac ion channel 
function. Cardiovasc Res 2006, 69:798-807. 
119. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, 
Hofmann F, et al: Patient-specific induced pluripotent stem-cell models for long-QT 
syndrome. N Engl J Med 2010, 363:1397-1409. 
120. Adzhubei I, Jordan DM, Sunyaev SR: Predicting functional effect of human missense 
mutations using PolyPhen-2. Curr Protoc Hum Genet 2013, Chapter 7:Unit7 20. 
121. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC: SIFT web server: predicting effects of 
amino acid substitutions on proteins. Nucleic Acids Res 2012, 40:W452-457. 
122. Reva B, Antipin Y, Sander C: Predicting the functional impact of protein mutations: 
application to cancer genomics. Nucleic Acids Res 2011, 39:e118. 
123. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tsuchihashi T, McManus 
MT, Schwartz RJ, Srivastava D: Dysregulation of cardiogenesis, cardiac conduction, and cell 
cycle in mice lacking miRNA-1-2. Cell 2007, 129:303-317. 
124. Borel C, Antonarakis SE: Functional genetic variation of human miRNAs and phenotypic 
consequences. Mamm Genome 2008, 19:503-509. 
125. Kim J, Bartel DP: Allelic imbalance sequencing reveals that single-nucleotide 
polymorphisms frequently alter microRNA-directed repression. Nat Biotechnol 2009, 
27:472-477. 
126. Ryan BM, Robles AI, Harris CC: Genetic variation in microRNA networks: the implications 
for cancer research. Nat Rev Cancer 2010, 10:389-402. 
127. Saunders MA, Liang H, Li WH: Human polymorphism at microRNAs and microRNA target 
sites. Proc Natl Acad Sci U S A 2007, 104:3300-3305. 
128. Mencia A, Modamio-Hoybjor S, Redshaw N, Morin M, Mayo-Merino F, Olavarrieta L, Aguirre 
LA, del Castillo I, Steel KP, Dalmay T, et al: Mutations in the seed region of human miR-96 
are responsible for nonsyndromic progressive hearing loss. Nat Genet 2009, 41:609-613. 
129. Lewis MA, Quint E, Glazier AM, Fuchs H, De Angelis MH, Langford C, van Dongen S, Abreu-
Goodger C, Piipari M, Redshaw N, et al: An ENU-induced mutation of miR-96 associated 
with progressive hearing loss in mice. Nat Genet 2009, 41:614-618. 
130. Kunej T, Skok DJ, Horvat S, Dovc P, Jiang Z: The glypican 3-hosted murine mir717 gene: 
sequence conservation, seed region polymorphisms and putative targets. Int J Biol Sci 
2010, 6:769-772. 
131. Dorn GW, 2nd, Matkovich SJ, Eschenbacher WH, Zhang Y: A human 3' miR-499 mutation 
alters cardiac mRNA targeting and function. Circ Res 2012, 110:958-967. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 201 
132. Ohanian M, Humphreys DT, Anderson E, Preiss T, Fatkin D: A heterozygous variant in the 
human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand 
abundance. BMC Genet 2013, 14:18. 
133. Han SJ, Marshall V, Barsov E, Quinones O, Ray A, Labo N, Trivett M, Ott D, Renne R, Whitby 
D: KSHV encoded microRNA Single Nucleotide Polymorphisms Identified in Clinical 
Samples can affect microRNA Processing, Level of Expression and Silencing Activity. J Virol 
2013. 
134. Amin AS, Pinto YM, Wilde AA: Long QT syndrome: beyond the causal mutation. J Physiol 
2013. 
135. Chockalingam P, Wilde A: The multifaceted cardiac sodium channel and its clinical 
implications. Heart 2012, 98:1318-1324. 
136. Remme CA, Wilde AA, Bezzina CR: Cardiac sodium channel overlap syndromes: different 
faces of SCN5A mutations. Trends Cardiovasc Med 2008, 18:78-87. 
137. Miyazaki T, Mitamura H, Miyoshi S, Soejima K, Aizawa Y, Ogawa S: Autonomic and 
antiarrhythmic drug modulation of ST segment elevation in patients with Brugada 
syndrome. J Am Coll Cardiol 1996, 27:1061-1070. 
138. Pappone C, Radinovic A, Manguso F, Vicedomini G, Sala S, Sacco FM, Ciconte G, Saviano M, 
Ferrari M, Sommariva E, et al: New-onset atrial fibrillation as first clinical manifestation of 
latent Brugada syndrome: prevalence and clinical significance. Eur Heart J 2009, 30:2985-
2992. 
139. Shimizu W, Antzelevitch C, Suyama K, Kurita T, Taguchi A, Aihara N, Takaki H, Sunagawa K, 
Kamakura S: Effect of sodium channel blockers on ST segment, QRS duration, and 
corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol 2000, 
11:1320-1329. 
140. Benito B, Brugada R, Perich RM, Lizotte E, Cinca J, Mont L, Berruezo A, Tolosana JM, Freixa X, 
Brugada P, Brugada J: A mutation in the sodium channel is responsible for the association 
of long QT syndrome and familial atrial fibrillation. Heart Rhythm 2008, 5:1434-1440. 
141. Zhang L, Timothy KW, Vincent GM, Lehmann MH, Fox J, Giuli LC, Shen J, Splawski I, Priori SG, 
Compton SJ, et al: Spectrum of ST-T-wave patterns and repolarization parameters in 
congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000, 102:2849-
2855. 
142. Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, Schulze-Bahr E, Fukuhara S, 
Mochizuki N, Makiyama T, et al: The E1784K mutation in SCN5A is associated with mixed 
clinical phenotype of type 3 long QT syndrome. J Clin Invest 2008, 118:2219-2229. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 202 
143. Bezzina C, Veldkamp MW, van Den Berg MP, Postma AV, Rook MB, Viersma JW, van Langen 
IM, Tan-Sindhunata G, Bink-Boelkens MT, van Der Hout AH, et al: A single Na(+) channel 
mutation causing both long-QT and Brugada syndromes. Circ Res 1999, 85:1206-1213. 
144. McNair WP, Ku L, Taylor MR, Fain PR, Dao D, Wolfel E, Mestroni L, Familial Cardiomyopathy 
Registry Research G: SCN5A mutation associated with dilated cardiomyopathy, conduction 
disorder, and arrhythmia. Circulation 2004, 110:2163-2167. 
145. Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, Horton SC, Rodeheffer RJ, 
Anderson JL: Sodium channel mutations and susceptibility to heart failure and atrial 
fibrillation. JAMA 2005, 293:447-454. 
146. Roepke TK, King EC, Reyna-Neyra A, Paroder M, Purtell K, Koba W, Fine E, Lerner DJ, 
Carrasco N, Abbott GW: Kcne2 deletion uncovers its crucial role in thyroid hormone 
biosynthesis. Nat Med 2009, 15:1186-1194. 
147. Furukawa T, Ono Y, Tsuchiya H, Katayama Y, Bang ML, Labeit D, Labeit S, Inagaki N, Gregorio 
CC: Specific interaction of the potassium channel beta-subunit minK with the sarcomeric 
protein T-cap suggests a T-tubule-myofibril linking system. J Mol Biol 2001, 313:775-784. 
148. Bianchi L, Shen Z, Dennis AT, Priori SG, Napolitano C, Ronchetti E, Bryskin R, Schwartz PJ, 
Brown AM: Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and 
trafficking in long QT syndrome. Hum Mol Genet 1999, 8:1499-1507. 
149. Duggal P, Vesely MR, Wattanasirichaigoon D, Villafane J, Kaushik V, Beggs AH: Mutation of 
the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms 
of Long-QT syndrome. Circulation 1998, 97:142-146. 
150. Ravn LS, Aizawa Y, Pollevick GD, Hofman-Bang J, Cordeiro JM, Dixen U, Jensen G, Wu Y, 
Burashnikov E, Haunso S, et al: Gain of function in IKs secondary to a mutation in KCNE5 
associated with atrial fibrillation. Heart Rhythm 2008, 5:427-435. 
151. Delpon E, Cordeiro JM, Nunez L, Thomsen PE, Guerchicoff A, Pollevick GD, Wu Y, Kanters JK, 
Larsen CT, Burashnikov E, et al: Functional Effects of KCNE3 Mutation and its Role in the 
Development of Brugada Syndrome. Circ Arrhythm Electrophysiol 2008, 1:209-218. 
152. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF: Arrhythmia in 
hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J 1981, 46:168-172. 
153. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-
Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J: Genetic variations of KCNQ1, 
KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med 
2004, 82:182-188. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 203 
154. Van Laer L, Carlsson PI, Ottschytsch N, Bondeson ML, Konings A, Vandevelde A, Dieltjens N, 
Fransen E, Snyders D, Borg E, et al: The contribution of genes involved in potassium-
recycling in the inner ear to noise-induced hearing loss. Hum Mutat 2006, 27:786-795. 
155. Abbott GW, Goldstein SA: Potassium channel subunits encoded by the KCNE gene family: 
physiology and pathophysiology of the MinK-related peptides (MiRPs). Mol Interv 2001, 
1:95-107. 
156. Aatre RD, Day SM: Psychological issues in genetic testing for inherited cardiovascular 
diseases. Circ Cardiovasc Genet 2011, 4:81-90. 
157. Hall AE, Burton H: Legal and ethical implications of inherited cardiac disease in clinical 
practice within the UK. J Med Ethics 2010, 36:762-766. 
158. Leachman SAM, D.G; Angrist, M.; Gray, S.W.; Bradbury, A.R.; Vorhaus, D.B.: Direct-to-
Consumer Genetic Testing: Personalized Medicine in Evolution. In 2011 Educational Book. 
Edited by University A. American Society of Clinical Oncology; 2011 
159. van El CG, Cornel MC, Borry P, Hastings RJ, Fellmann F, Hodgson SV, Howard HC, Cambon-
Thomsen A, Knoppers BM, Meijers-Heijboer H, et al: Whole-genome sequencing in health 
care: recommendations of the European Society of Human Genetics. Eur J Hum Genet 
2013, 21:580-584. 
160. Harris A, Kelly SE, Wyatt S: Counseling customers: emerging roles for genetic counselors in 
the direct-to-consumer genetic testing market. J Genet Couns 2013, 22:277-288. 
161. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz 
PJ, Stanton M, et al: Allelic variants in long-QT disease genes in patients with drug-
associated torsades de pointes. Circulation 2002, 105:1943-1948. 
162. Yap YG, Camm AJ: Drug induced QT prolongation and torsades de pointes. Heart 2003, 
89:1363-1372. 
163. Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH: Timing of new 
black box warnings and withdrawals for prescription medications. JAMA 2002, 287:2215-
2220. 
 
 
Stellenbosch University  http://scholar.sun.ac.za
  Page 204 
CHAPTER 10: CANDIDATE ’S CONTRIBUTIONS 
CHAPTER 1 
1.5.2 Review 1: The Genetic Basis of Long QT and Short QT Syndromes: A Mutation Update 
 First author 
 Analysis and Interpretation of data 
 Writing of manuscript 
1.5.3 Review 2: The Genetic Basis of Brugada Syndrome: A Mutation Update 
 First author  
 Analysis and Interpretation of data 
 Writing of manuscript 
1.5.4 Editorial: Long QT Testing: Implications for Complex Diagnosis in Personalised 
Medicine 
 Co-author 
 Planning, Discussing and Writing Manuscript 
CHAPTER 2 
Paper 1: Long QT Syndrome in South Africa: The Results of Comprehensive Genetic 
Screening 
 First author 
 Planning of study 
 Development of laboratory protocols and lab work 
 Analysis and Interpretation of data 
 Writing of manuscript 
CHAPTER 3 
Paper 2: Mutations in Danish Patients with Long QT Syndrome and Identification of a Large 
Founder Family with p.F29L in KCNH2 
 Shared first author 
 Data acquisition 
 Analysis and Interpretation of data 
 Critical revision of manuscript 
Stellenbosch University  http://scholar.sun.ac.za
  Page 205 
CHAPTER 4 
Paper 3: The Role of CAV3 in Long QT Syndrome: Clinical and Functional Assessment of a 
Caveolin-3/Kv11.1 Double Heterozygote versus Caveolin-3 Single Heterozygote 
 First author 
 Planning and coordinating study 
 Analysis and Interpretation of data 
 Writing of manuscript 
Paper 4: MicroRNAs in Cardiac Arrhythmia: The Sequence Variation of miR-1 and miR-133a 
in Long QT Syndrome 
 First author 
 Planning and coordinating study 
 Analysis and Interpretation of data 
 Writing and corresponding of manuscript 
CHAPTER 5 
Paper 5: Flecainide Provocation Reveals Concealed Brugada Syndrome in a Long QT 
Syndrome Family with a Novel L1786Q Mutation in SCN5A 
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 Analysis and Interpretation of data 
Paper 6: High Prevalence of Long QT Syndrome–Associated SCN5A Variants in Patients 
with Early-Onset Lone Atrial Fibrillation 
 Co-author 
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CHAPTER 11: SUPPLEMENTARY MATERIALS 
11.1 LIST OF ABBREVIATIONS 
Abbreviation Definition 
AA African American 
aa amino acid 
AF atrial fibrillation 
aLQTS acquired long QT syndrome 
AP action potential 
APD action potential duration 
AS Andersen syndrome 
ATS Andersen-Tawil syndrome 
AVN atrioventricular node 
AVNRT atrioventricular nodal reentrant tachycardia 
AVRT atrioventricular reentrant tachycardia 
BrS Brugada syndrome 
CA cardiac arrest 
CAD coronary artery disease 
CAE capillary array electrophoresis 
CCD cardiac conduction disease 
CCS cardiac conduction system 
cDNA coding DNA 
CEU Utah residents with ancestry from northern and western Europe 
CHF congestive heart failure 
CHO Chinese hamster ovary 
cLQTS congenital long QT syndrome 
CNV copy number variant 
DAD delayed-afterdepolarisation 
DCM dilated cardiomyopathy 
DHPLC denaturing high performance liquid chromatography 
DK Denmark / of Danish origin 
dLQTS drug-related long QT syndrome 
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DM distal myopathy 
EA European American 
EAD early-afterdepolarisation 
ECG electrocardiogram 
EMD electromechanical dissociation 
EP  electrophysiology 
EPS programmed electrical stimulation 
ESP  exome sequencing project 
EVS exome variant server 
FBS foetal bovine serum 
FSHD Facioscapulohumeral muscular dystrophy 
gDNA genomic DNA 
GFP green fluorescent protein 
HB bundle of His 
H-CK hyperCKemia 
HCM hypertrophic cardiomyopathy 
HEK human embryonic kidney 
HWE Hardy-Weinberg equilibrium 
IB immunoblot 
ICD implantable cardioverter defibrillator 
IP immunoprecipitation 
JLNS Jervell-Lange-Nielsen syndrome 
LBB left bundle branch 
LGMD limb girdle muscular dystrophy 
LQTS long QT syndrome 
LVEF left ventricular ejection fraction 
MAF minor allele frequency 
MCS morphology-combination-score 
MEF2 myocyte enhancer factor-2 
MEM minimal essential medium 
MFE minimum free energy 
MI myocardial infarction 
miRNA micro ribonucleic acid 
miRNA* the degraded/passenger strand of miRNA duplex 
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MLPA multiplex-ligation-dependent amplification 
mRNA messenger ribonucleic acid 
multi-CE-SSCP 
multiplex-capillary electrophoresis - single strand conformation 
polymorphism 
MVT monomorphic ventricular tachycardia 
NGS next generation sequencing 
nt nucleotide 
PAS Per-Arnt-Sim 
PCR polymerase chain reaction 
ped pedigree 
PF Purkinje fibre 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
pre-miRNA preliminary microRNA 
pri-miRNA primary microRNA 
PVS programmed ventricular stimulation 
PVT polymorphic ventricular tachycardia 
QTc corrected QT interval 
RBB right bundle branch 
RISC RNA-induced silencing complex 
RMD rippling muscular dystrophy 
RVD right ventricular dysplasia 
RVOT right ventricular outflow tract 
RWS Romano-Ward syndrome 
SADS sudden arrhythmia death syndrome 
SAN sinoatrial node 
SCD sudden cardiac death 
SD standard deviation 
SEM standard error of the mean 
SIDS sudden infant death syndrome 
SNP single nucleotide polymorphism 
SNP single nucleotide polymorphism 
SQTS short QT syndrome 
SRF serum response factor 
SSCP single strand conformation polymorphism 
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SUNDS sudden unexpected nocturnal death syndrome 
SVT supraventricular tachycardia 
TdP torsades de pointes 
TDR transmural dispersion of repolarisation 
TS Timothy syndrome 
TTX tetrodotoxin 
UTR un-translated region 
VF ventricular fibrillation 
VT ventricular tachycardia 
WPW Wolff-Parkinson-White 
WT wild type 
Y2H yeast-2-hybrid 
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11.2 TABLE OF GENES EXAMINED IN THE DISSERTATION 
Genes NCBI ID Chromosome Gene product NCBI ID 
KCNQ1 NM_000218 11p15.5 Kv7.1 NP_000209 
KCNH2 NM_000238 7q35-7q36 Kv11.1 NP_000229 
SCN5A NM_198056 3p21 Nav1.5 NP_932173 
KCNE1 NM_000219 21p22 minK NP_000210 
KCNE2 NM_172201 21p22 MiRP1 NP_75195 
KCNE3 NM_005472 11q13.4 MiRP2 NP_005463 
KCNE4 NM_080671 2q36.1 MiRP3 NP_542402 
KCNE1L NM_0122822 Xq22.3 MiRP4 NP_036414 
CAV3 NM_001234 3p25 caveolin-3 NP_001225 
miR-1-1 NR_029780 20q13.33 MIR-1   
miR-1-2 NR_029662 18q11.2 MIR-1   
miR-133A-1 NR_029675 18q11.2 MIR-133A   
miR-133A-2 NR_029676 20q13.33 MIR-133A   
11.3 CANDIDATE’S PUBLICATION LIST 
11.3.1 CARDIOVASCULAR DISEASES 
 Hedley PL, Kanters JK, Dembic M, Jespersen T, Skibsbye L, Aidt FH, et al. The role of 
CAV3 in long QT syndrome: clinical and functional assessment of a Caveolin-3/Kv11. 1 
double heterozygote versus Caveolin-3 single heterozygote. 
Circ Cardiovasc Gen. 2013;6(5):452-461 
 Hedley PL, Durrheim GA, Hendricks F, Corfield VA, Jespersgaard C, Støvring B, et al. Long 
QT syndrome in South Africa: the results of comprehensive genetic screening. 
Cardiovascular Journal of Africa. 2013;24(6):231-237 
 Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Møller DV, Hedley PL, et al. Metabolic 
rather than body composition measurements are associated with lower serum 
natriuretic peptide concentrations in normal weight and obese men. Am J Hypertens. 
2013; published online doi: 10.1093/ajh/hpt145 
 Hagen CM, Aidt FH, Hedley PL, Jensen MK, Havndrup O, Kanters JK, et al. Mitochondrial 
haplogroups modify the risk of developing hypertrophic cardiomyopathy in a Danish 
population. PloS one. 2013;8:e71904. 
 Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Moller DV, Hedley PL, et al. Relative 
atrial natriuretic peptide deficiency and inadequate renin and angiotensin II 
suppression in obese hypertensive men. Hypertension. 2013;62:147-153. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 211 
 Hagen CM, Aidt FA, Havndrup O, Hedley PL, Jespersgaard C, Jensen M, et al. MT-CYB 
mutations in hypertrophic cardiomyopathy. Molecular Genetics & Genomic Medicine. 
2013 1(1),54-65. 
 Godiksen MTN, Kinnear C, Ravnsborg T, Højrup P, Granström S, Laursen IA, Hedley PL, 
et al., Feline hypertrophic cardiomyopathy associated with the p.A31P mutation in 
cMyBP-C is caused by production of mutated cMyBP-C with reduced binding to Actin. 
Open J Vet Med, 2013, 3, 95-103. 
 Olesen MS, Yuan L, Liang B, Holst AG, Nielsen N, Nielsen JB, Hedley PL, et al. High 
prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset 
lone atrial fibrillation. Circ Cardiovasc Genet. 2012;5:450-459. 
 Nyegaard M, Overgaard MT, Sondergaard MT, Vranas M, Behr ER, Hildebrandt LL,  Lund 
J, Hedley PL, et al. Mutations in calmodulin cause ventricular tachycardia and sudden 
cardiac death. AJHG. 2012;91:703-712. 
 Andersen PS, Hedley PL, Page SP, Syrris P, Moolman-Smook JC, Mckenna WJ, et al. A 
novel myosin essential light chain mutation causes hypertrophic cardiomyopathy with 
late onset and low expressivity. Biochem Res Int. 2012;2012:685108. 
 Dembic M, Brusich S, Hedley PL, de Villiers CP, Čubranić Z, Kanters JK, et al. Long QT 
syndrome - a cause of sudden death. Cardiologia Croatica, 2012 7(11-12), 263-275. 
 Olesen MS, Jespersen T, Nielsen JB, Liang B, Moller DV, Hedley P, et al. Mutations in 
sodium channel beta-subunit scn3b are associated with early-onset lone atrial 
fibrillation. Cardiovasc Res. 2011;89:786-793. 
 Moller DV, Hedley PL, Olesen M, Kanters J, Svendsen JH, Christiansen M. [short QT 
syndrome as an inherited condition]. [Article in Danish]. Ugeskr Laeger. 2011;173:420-
424. 
 Hedley PL, Haundrup O, Andersen PS, Aidt FH, Jensen M, Moolman-Smook JC, et al. The 
KCNE genes in hypertrophic cardiomyopathy: A candidate gene study. J Negat Results 
Biomed. 2011;10:12. 
 Szeliga MA, Hedley PL, Green CP, Moller DV, Christiansen M. Long QT syndrome - a 
genetic cardiac channelopathy. Kardiologia polska. 2010;68:575-583. 
 Moller DV, Pecini R, Gustafsson F, Hassager C, Hedley P, Jespersgaard C, et al. Hereditary 
hemochromatosis (HFE) genotypes in heart failure: Relation to etiology and prognosis. 
BMC medical genetics. 2010;11:117. 
 Christiansen M, Hedley PL. Long QT testing: Implications for complex diagnosis in 
personalized medicine. Personalized Medicine. 2010;7:125-127. 
Stellenbosch University  http://scholar.sun.ac.za
  Page 212 
 Bastiaenen R, Hedley PL, Christiansen M, Behr ER. Therapeutic hypothermia and 
ventricular fibrillation storm in early repolarization syndrome. 
Heart Rhythm. 2010;7:832-834. 
 Moller DV, Pham TT, Gustafsson F, Hedley P, Ersboll MK, Bundgaard H, et al. The role of 
Lamin A/C mutations in Danish patients with idiopathic dilated cardiomyopathy. Eur J 
Heart Fail. 2009;11:1031-1035. 
 Moller DV, Andersen PS, Hedley P, Ersboll MK, Bundgaard H, Moolman-Smook J, et al. 
The role of sarcomere gene mutations in patients with idiopathic dilated 
cardiomyopathy. EJHG. 2009;17:1241-1249. 
 Hedley PL, Jorgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, et al. 
The genetic basis of long QT and short QT syndromes: A mutation update. Hum Mutat. 
2009;30:1486-1511. 
 Hedley PL, Jorgensen P, Schlamowitz S, Moolman-Smook J, Kanters JK, Corfield VA, et al. 
The genetic basis of Brugada syndrome: A mutation update. Hum Mutat. 2009;30:1256-
1266. 
 Andersen PS, Havndrup O, Hougs L, Sorensen KM, Jensen M, Larsen LA, Hedley PL, et al. 
Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere 
encoding genes in Danish hypertrophic cardiomyopathy patients and relatives. Hum 
Mutat. 2009;30:363-370. 
 Schwartz PJ, Vanoll E, Crotti L, Spazzolim C, Ferrandl C, Goosen A, Hedley P, et al. Neural 
control of heart rate is an arrhythmia risk modifier in long QT syndrome. JACC. 
2008;51:920-929. 
 Hofman-Bang J, Behr ER, Hedley P, Tfelt-Hansen J, Kanters JK, Haunsoe S, et al. High-
efficiency multiplex capillary electrophoresis single strand conformation polymorphism 
(multi-CE-SSCP) mutation screening of SCN5A: A rapid genetic approach to cardiac 
arrhythmia. Clin Genet. 2006;69:504-511. 
 Brink PA, Crotti L, Corfield V, Goosen A, Durrheim G, Hedley P, et al. Phenotypic 
variability and unusual clinical severity of congenital long-QT syndrome in a founder 
population. Circulation. 2005;112:2602-2610. 
11.3.2 PRENATAL DIAGNOSIS AND REPRODUCTIVE MEDICINE 
 Svendsen PF, Christiansen M, Hedley PL, Nilas L, Pedersen SB, Madsbad S. Adipose 
expression of adipocytokines in women with polycystic ovary syndrome. Fertility and 
sterility. 2012;98:235-241 
Stellenbosch University  http://scholar.sun.ac.za
  Page 213 
 Jorgensen JM, Hedley PL, Gjerris M, Christiansen M. Ethical issues related to screening 
for preeclampsia. Bioethics. 2012 Sep 20. doi: 10.1111/j.1467-8519.2012.02005.x. 
 Hedley PL, Placing S, Wojdemann K, Carlsen AL, Shalmi AC, Sundberg K, et al. Free leptin 
index and papp-a: A first trimester maternal serum screening test for pre-eclampsia. 
Prenatal diagnosis. 2010;30:103-109. 
 Christiansen M, Pihl K, Hedley PL, Gjerris AC, Lind PO, Larsen SO, et al. Adam 12 may be 
used to reduce the false positive rate of first trimester combined screening for Down 
syndrome. Prenatal diagnosis. 2010;30:110-114. 
 Laigaard J, Pedersen NG, Larsen SO, Hedley PL, Wojdemann K, Gjerris AC, et al. Adam12 
in first trimester maternal serum from pregnancies conceived by assisted reproduction 
techniques (ART). Prenatal diagnosis. 2009;29:628-629. 
 Laigaard J, Larsen SO, Pedersen NG, Hedley PL, Gjerris AC, Wojdemann KR, et al. Adam 
12-S in first trimester: fetal gender, smoking and maternal age influence the maternal 
serum concentration. Prenatal diagnosis. 2009;29:525-527 
 Hedley P, Pihl K, Krebs L, Larsen T, Christiansen M. Leptin in first trimester pregnancy 
serum: No reduction associated with small-for-gestational-age infants. Reproductive 
biomedicine online. 2009;18:832-837. 
 Hedley P, Christiansen M. Serum leptin in first-trimester down syndrome pregnancies. 
Prenatal diagnosis. 2008;28:475-477. 
11.3.3 IMMUNOGENETICS 
 Adu B, Dodoo D, Adukpo S, Hedley PL, Arthur FK, Gerds TA, et al. Fc gamma receptor IIIB 
(FcγRIIIB) polymorphisms are associated with clinical malaria in Ghanaian children. 
PloS one. 2012;7:e46197. 
 Adu B, Dodoo D, Adukpo S, Gyan BA, Hedley PL, Goka B, et al. Polymorphisms in the 
RNASE3 gene are associated with susceptibility to cerebral malaria in Ghanaian 
children. PloS one. 2011;6:e29465. 
11.3.4 PHARMACOGENETICS 
 Steinmetz J, Jespersgaard C, Dalhoff K, Hedley P, Abildstrom H, Christiansen M, et al. 
Cytochrome p450 polymorphism and postoperative cognitive dysfunction. Minerva 
anestesiologica. 2012;78:303-309. 
Stellenbosch University  http://scholar.sun.ac.za
